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There is an unmet need in prostate cancer for effective therapies to prevent
the emergence of resistance. Combinations of small molecules targeting key
pathways are a promising strategy. I investigated how populations of the early
metastatic prostate cancer cell line LNCaP respond at the proteomic and pheno-
typic levels to six clinically-relevant, one-drug treatments and their 15 pairs of
two-drug combinations, administered simultaneously to treatment-naive cells.
After 24 hours of drug addition for all 21 drug treatments I measured 52 total-
proteins by selected-reaction monitoring mass-spectrometry based proteomics
(SRM), 20 phospho-proteins, and 50 total-proteins by reverse-phase protein ar-
rays (RPPA). I measured phenotypic effects on cell proliferation and apoptosis
in all conditions using phase-contrast and fluorescence microscopy. Network
analysis identified (phospho)-proteins with large responses to drug treatments
that are druggable with FDA-approved drugs or have nearest-neighbors that
are druggable.
A total of ten drugs targeting these nearest responder (phospho)-proteins
were tested in single, double, and triple combinations. I found that 7 out of
10 triple combinations co-targeting androgen receptor and PI3K pathways were
no more effective than the two-drug combination at the doses tested: PRKC (en-
zastaurin), MAPK (losmapimod), STAT3 (napabucasin), HDAC (panobinostat),
SRC (saracatinib), casein kinase (silmitasertib), MAPK (ulixertinib). I was un-
able to determine the relative efficacy of aurora kinase B (barasertib), 14-3-3 in-
hibor (BV02) and their combinations. For one drug tested (dinaciclib, CDK1/2
inhibitor) I found increased efficacy with PI3K signaling inhibition (MK2206,
AKT1/2 inhibitor).
I propose a simple model where blocking PI3K signaling in LNCaP cells
causes a partial inhibition of the cell cycle G1/S transition through hypo-
phosphorylation of RB and hypo-phosphorylation of CDK2 at the G2/M transi-
tion. These effects can be enhanced by co-targeting PI3K signaling and drivers
of the cell cycle using the CDK1/2 inhibitor dinaciclib.
I also investigated how proteins that interact with the androgen receptor
change in response to perturbation in a prostate cancer context (VCaP cell line).
I identified 111 proteins with affinity purification mass spectrometry (AP-MS).
These proteins have diverse functions and many have not been reported in the
literature. I found that treatment with an antagonist (enzalutamide) has mini-
mal effects on the interactors. Interactors such as metadherin (MDTH) and chro-
mosome transmission fidelity factor 8 (CHTF8) are recurrently altered in patient
cohorts. Metadherin is recurrently amplified and may represent a promising
drug target.
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CHAPTER 1
INTRODUCTION: DESIGNING COMBINATION THERAPY FOR
PROSTATE CANCER
1.1 Why combination therapy?
There is an unmet need in prostate cancer for effective therapies against
metastatic disease [Attard et al., 2016]. Recently, studies of large patient co-
horts have identified numerous recurrent alterations [Taylor et al., 2010]. These
alterations form the basis for current targeted therapies against AR signal-
ing and a rationale for novel therapy development against cell cycle, DNA
repair, ETS fusions, chromatin remodelling, MAPK pathway, Wnt pathway,
and PI3K pathway [Spratt et al., 2016], [Rodrigues et al., 2017]. The emer-
gence of resistance to current therapies targeting androgen receptor signal-
ing and taxane chemotherapy may be overcome with combination therapy
[Watson et al., 2015], [Komura et al., 2016], [Dumontet and Sikic, 1999]. The
ability to overcome the emergence of resistance with combination therapy treat-
ing HIV and tuberculosis suggests it may be a promising approach for prostate
cancer [Bock and Lengauer, 2012]. Theoretical evolutionary dynamics studies
also suggest combination therapy may be able to overcome the emergence
of resistance [Bozic et al., 2013]. Drug combinations that are effective against
tumor cells may not cause a concomitant multiplicative increase in toxicity
[Leha´r et al., 2009].
Development of combination therapy is challenging partly due to a search
space that grows exponentially with the library size, number of drugs
in a combination, doses, exposure history, administration schedule (i.e.,
1
whether the drugs are given simultaneously or staggered), and other fac-
tors [Zimmer et al., 2016]. One pre-clinical approach to developing combi-
nation therapy, termed perturbation biology investigates how populations of
treatment-naive cells in monoculture respond to one- and two-drug treatments
at the level of (phospho)-proteins and cellular phenotypes after short-term ex-
posure; these short-term (phospho)-proteomic responses may represent resis-
tance mechanisms that may be targeted in novel drug combinations leading
to increased efficacy [Korkut et al., 2015]. Theoretical evolutionary dynamics
has identified tumor population and growth rate as key factors in the proba-
bility that resistance emerges; therefore, drug combinations that decrease tu-
mor population and/or growth rate may prevent the emergence of resistance
[Bozic et al., 2013].
1.2 The perturbation biology approach
The perturbation biology approach is a promising strategy to develop combi-
nation therapy and learn how cellular networks respond to and resist small
molecular perturbations [Korkut et al., 2015]. Perturbation biology involves
measuring how prostate cancer cells respond to clinically-relevant drug per-
turbations to nominate mechanisms of resistance that in turn may be overcome
with drug combinations – an approach that has worked previously in BRAF-
resistant melanoma [Korkut et al., 2015].
The most useful molecular measurements to uncover short-term resis-
tance mechanisms may be (phospho)-proteins because proteins are the tar-
gets of most drugs and are key components of biochemical networks
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[Aebersold and Mann, 2016]. Measurements of (phospho)-proteins after drug
response led to a key discovery in the understanding of prostate cancer signal
transduction networks, where reciprocal feedback inhibition between AR and
PI3K signaling provides resistance mechanisms to one-drug treatments target-
ing either pathway [Carver et al., 2011]. Additionally, proteomics has provided
numerous insights in cancer including subtyping [Tyanova et al., 2016], con-
necting somatic mutations to signaling [Mertins et al., 2016], and understanding
the functions of genes [Wang et al., 2017]. Of the various types of proteomics,
targeted proteomics provides favorable sample throughput and sensitivity for
perturbation biology studies [Ebhardt et al., 2015], [Lu et al., 2016].
To develop a combination therapy for prostate cancer I chose the LNCaP
cell line model of early metastatic prostate cancer; it is PTEN-deficient, AR
sensitive, and has an ETS-family rearrangement; all of which are recur-
rent alterations in early metastatic prostate cancer patients [Taylor et al., 2010].
LNCaP was derived from the lymph node of a patient with metastatic
prostate cancer and is sometimes considered the dominant model system
in the field [Watson et al., 2015]. I chose to use two complementary plat-
forms for targeted proteomics: selected reaction monitoring mass spectrome-
try (SRM) and reverse-phase protein arrays (RPPA). I performed manual lit-
erature curation to choose targets and developed SRM assays for 52 total-
protein measurements. To increase coverage of cancer-relevant signaling pro-
teins and phosphosites I used a commonly used set of RPPA antibodies
[Lu et al., 2016]. I selected six clinically-relevant drugs and their doses based
on a literature search: AR inhibitor enzalutamide [Tran et al., 2009], chemother-
apy docetaxel [Dumontet and Sikic, 1999], SRC inhibitor dasatinib [Nam, 2005],
AKT inhibitor MK2206 [Yap et al., 2011], and MTOR inhibitor temsirolimus
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[Wang et al., 2011].
After performing all one- and two-drug combinations I used network anal-
ysis of the (phospho)-proteins responses to nominate resistance mechanisms
and additional drug combinations to overcome them. One limitation to this
approach of studying LNCaP cells in monoculture is that microenvironment
cells have been shown to secrete factors that alter drug sensitivity and provide
resistance mechanisms [Ireland et al., 2016].
1.2.1 Hypothesis
Measuring how LNCaP cells respond to short-term one- and two-drug combi-
nations at the phenotypic and proteomic levels will reveal markers of response
and resistance that can be enhanced or blocked with novel drug combinations
leading to a highly potent cocktail. Such a potent cocktail works by lowering
the probability of resistance emerging through: shrinking the tumor population
size and/or targeting pre-existing resistant clones. A cocktail composed of tar-
geted therapies will have much greater effects on the tumor than concomitant
increases in toxicity to normal cells.
1.2.2 Aims
The first three aims were presented during my admission to candidacy exam
(ACE). Additional aims arose during progression of the research.
1. Perform perturbation biology experiments using targeted proteomics:
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• manually curate literature for proteins relevant for prostate cancer;
• manually curate literature for clinically-relevant drugs for prostate
cancer;
• collaborate with the Aebersold laboratory to develop targeted pro-
teomics assays (SRM);
• measure the phenotypic and proteomic effects of all one- and two-
drug combinations.
2. Analyze the resulting data to nominate:
• mechanisms of response and resistance;
• novel drug combinations to enhance or overcome these mechanisms
using network analysis.
3. Test network analysis predictions of novel drug combinations using phe-
notypic assays.
4. Evaluate novel drug combinations for testing in vivo mouse models.
5. Analyze perturbation data of AR-interacting proteins and prioritize can-
didates for drug combination development.
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Key Questions and Study Design
  How do LNCaP respond to clinically-relevant one- and two-drug combinations?
  Which additional drugs may enhance their activity?
A  Experimental design:  LNCaP cell line
        all one- and two-drug combinations 
  
B  Phenotypic & targeted proteomic measurements 
     following drug perturbations
C  Network analysis to understand drug resistance
     and predict new combinations to overcome it
D  Testing network analysis predictions of 
      drug combinations with phenotypic assays
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Figure 1.1: Overview of the experimental design, measurements, net-
work analysis predictions, and testing of analysis predictions.
(A) To develop combination therapy for AR-positive prostate cancer I
perturbed LNCaP cells with six-clinically relevant drugs and their corre-
sponding 15 drug pairs.
(B) Measurements are short-term drug response of populations of cells
with targeted proteomics and phenotypic assays.
(C) Data are placed on a human protein-protein, protein-drug network
from the PathwayCommons database [Cerami et al., 2011]. Network anal-
ysis nominated new drug combinations that may be effective alone or in
combination with the original drug set tested.
(D) Testing of network predictions lead to promising results for 1 out of 9
drugs tested.
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CHAPTER 2
METHODS - DESIGN OF PERTURBATIONS, MEASUREMENTS AND
ANALYSIS
2.1 Perturbations
An overview of the experimental design is depicted in figure 1.1. The process for
developing targeted proteomics assays using SRM is described on the following
pages in section 2.5.1 and figures 2.2 and 3.1.
2.1.1 LNCaP cell line model
The LNCaP cell line model of early metastatic prostate cancer was chosen for
this research; it is PTEN-deficient, AR sensitive, and has an ETS-family rear-
rangement; all of which are recurrent alterations in early metastatic prostate
cancer patients [Taylor et al., 2010]. LNCaP was derived from the lymph node
of a patient with metastatic prostate cancer and is sometimes considered the
dominant model system in the field [Watson et al., 2015].The prostate cancer
cell line LNCaP clone FGC was ordered from ATCC and used throughout this
study. Cultures were maintained in a humid 5% CO2 atmosphere at 37°C and
grown in RPMI-1640 medium supplemented with 10% heat-inactivated fetal
bovine serum, 100 units/ml each of penicillin and streptomycin, and 2mM L-
glutamine. Cells were used at less than 25 passages for all experiments. For
phenotypic assays, cells were seeded in 96-well plastic bottom plates at 12,500
cells per well in biological triplicate for all conditions. For proteomics assays
cells were seeded in 10cm petri dishes at 2 million cells per dish in biological
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triplicate for all conditions. Cells were left at room temperature for 20 minutes
for even seeding and placed in an incubator overnight.
2.1.2 Drug selection and treatments
Drug concentrations were estimated from the literature as IC50 values in pheno-
typic assays: bez235 500 nM, dasatinib 100 nM, docetaxel 10 nM, enzalutamide
10 µM, MK2206 1 µM, temsirolimus 100 nM. Drugs were used at the same con-
centration for singles and paired combinations. Drug dilutions were prepared
such that the same volume of DMSO is added for each single, combination, and
DMSO vehicle control. For proteomics samples, the 10cm dishes were placed in
an incubator after drug addition and cells were scraped after 24 hours, pelleted,
and frozen at -80°C. The sample layouts were not randomized and the exper-
imenters were not blinded to the experimental conditions to minimize confu-
sion during manual labeling and pipetting. For phenotypic measurements, a
green-fluorescent, apoptosis-indicating reagent (NucView 488) was added con-
currently with drugs to all wells. The 96-well plates were placed inside an au-
tomated microscope for live-cell imaging (IncuCyte ZOOM, Essen Biosciences),
which resides in a humid 5% CO2 atmosphere at 37°C incubator.
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Figure 2.1: Drug-target selection and doses. Drugs were chosen by man-
ual curation of the literature and clinical trials for clinically-relevant drugs.
Several drugs were chosen targeting PI3K/AKT signaling because PTEN
loss is a recurrent alteration in prostate cancer and in the LNCaP cell line.
Drugs had to have passed phase I trials in the USA for any indication.
Although docetaxel is a chemotherapeutic agent and not a targeted agent,
it was chosen because it is a standard of care. Doses were chosen based
on manual literature curation of IC50s in LNCaP or other cell lines if data
were not available for LNCaP.
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2.2 Measurement methods: phenotypic and proteomics quan-
titation of drug responses
2.2.1 Microscopy methods for phenotypic responses to drugs
Microscopy image acquisition and analysis
An automated, live-imaging microscope (IncuCyte ZOOM, Essen Biosciences)
was set to record 4 images per well at 10x magnification every 4 hours follow-
ing drug addition up to 120 hours using the control software (IncuCyte ZOOM
v2015). Approximate outlines of cells were imaged using phase contrast and
apoptosis was imaged using the green fluorescence channel. The microscope
is automated to scan all wells of a 96-well plate and was set to default param-
eters for autofocus and exposure time. Images were analyzed using the same
software. Several images were chosen to represent a broad spectrum of drug ef-
fects and controls to tune image analysis parameters, such that segmentation
and thresholding appeared reasonable to the eye in both the phase contrast
and green fluorescence channels. The image analysis pipeline was run in batch
mode over all images in the time series [Chapman et al., 2016].
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2.2.2 Targeted proteomics methods for drug effects on proteins
and phosphosites
Label-free selected reaction monitoring assay development
note: SRM assay development was performed by H. Alexander Ebhardt in the Aebersold
laboratory. I was invited by the Aebersold lab to oversee and assist in this development
over the course of two weeks. I also learned aspects of SRM assay development dur-
ing a laboratory rotation with Paul Tempst. I also co-authored a review article with H.
Alexander Ebhardt, which is Appendix A.
Preparation of a list of candidate protein targets. To identify proteins rele-
vant to prostate cancer I conducted a manual review of prostate cancer and
general cancer literature. Proteins with evidence of differential mRNA abun-
dance between primary metastatic samples were included. Approximately 400
proteins were mapped onto a human protein-protein interaction network and
linker nodes were identified using the Netbox algorithm. In total 490 proteins
were selected as candidates for targeted assay development shown in figure 2.2.
Sample preparation for label-free discovery MS/MS. Prostate cancer cells
LNCaP (approximately 3 million) were resuspended in 800 µL of lysis buffer
(8 M urea, 0.2% RapiGest, 0.1 M ammonium bicarbonate), vortexed for 10 s,
and shaken at 1000 rpm at room temperature for 10 min. Samples were soni-
cated (amplitude 90%, cycle 0.6) for 2 x 2 min at 4°C and centrifuged at 13,200
rpm for 10 min. The clear lysate was transferred to a new tube, the amount of
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Figure 2.2: Origins of candidate proteins for SRM assay development.
protein was determined using the micro BCA assay (Pierce, Thermo Scientific),
and the protein concentration was diluted to 5 mg/L with lysis buffer. The
sample was reduced using TCEP (tris-2-carboxyethylphophine) and alkylated
using iodoacetamide, and unreacted iodoacetamide was then neutralized with
N-acetyl-cystein. The samples were then diluted with 0.1 M ammonium bicar-
bonate and 0.2% RapiGest to a final concentration of less than 2 M urea. Proteins
were digested at a basic pH of 8.0 to 8.5 using sequence-grade modified trypsin
(Promega) at a ratio of 1:100 for 14 h at 37°C. Digestion was stopped by decreas-
ing the pH to less than 2 with formic acid. Samples were shaken another 30
min at 500 rpm at 37°C, followed by centrifugation at 13,200 rpm for 10 min to
remove any insoluble fractions. Samples were cleaned with C18 columns.
Sample fractionation by strong cation exchange chromatography and isoelec-
tric focusing. For strong cation-exchange fractionation, 500 µg of tryptic pep-
tides were loaded on a PolyLC column (PolyWAX LP 200 x 2.1 mm, 5 µm, 300-
A) for electrostatic repulsion liquid chromatography (ERLIC) fractionation us-
ing an Agilent 1200 HPLC chromatographic system. Buffer A: 90% ACN, 0.1%
acetic acid, buffer B: 30% ACN, 0.1% formic acid. Flow rate: 0.5 mL/min. Gra-
dient: 0-30% B in 40 min, 30-100% B in 40 min. One-minute fractions were
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collected in a 96-well plate.
For isoelectric fractionation (OffGel, Agilent), 500 µg of tryptic peptides were
loaded on a PolyLC column (PolyWAX LP 200 x 2.1 mm, 5 µm, 300-A) for elec-
trostatic repulsion liquid chromatography (ERLIC) fractionation using an Agi-
lent 1200 HPLC chromatographic system. Buffer A: 90% ACN, 0.1% acetic acid,
buffer B: 30% ACN, 0.1% formic acid. Flow rate: 0.5 mL/min. Gradient: 0-30%
B in 40 min, 30-100% B in 40 min. One-minute fractions were collected in a
96-well plate.
Label-free discovery MS/MS. Fractions were pooled into 10 samples for each
fractionation method separately. 10% of each sample was analyzed by LC
MS/MS in an Orbitrip LTQ Velos mass spectrometer (Thermo Fisher Scientific,
San Jose, CA) coupled to nano-LC (Proxeon, Odense, Denmark) equipped with
a a reversed-phase chromatography 12-cm column with an inner diameter of
75 µm, packed with 5 µm C18 particles (Nikkyo Technos, Japan). Chromato-
graphic gradients started at 97% buffer A and 3% buffer B with a flow rate of
300 nL/min and gradually increased to 93% buffer A and 7% bufferB in 1 min
and to 65%bufferA and 35% buffer B in 60 minutes. After each analysis, the
column was washed for 10 min with 10% buffer A and 90% buffer (buffer A:
0.1% formic acid in water; buffer B: 0.1% formic acid in acetonitrile). The mass
spectrometer was operated in positive ionization mode with nanospray voltage
set at 2.2 kV and source temperature at 250 C. Ultramark 1621 for the FT mass
analyzer was used for external calibration prior the analyses. Moreover, an in-
ternal calibration was also performed using the background poly-siloxane ion
signal at m/z 445.1200.
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The instrument was operated in DDA mode and full MS scans with 1 mi-
croscan at resolution of 60,000 were used over a mass range of m/z 2502000
with detection in the Orbitrap. Auto gain control (AGC) was set to 1e6, dy-
namic exclusion (60 s with a repeat duration of 30 s [repeat count = 1], and
an exclusion list size of 500 ions), and the charge state filter disqualifying singly
charged peptides was activated. Following each survey scan, the top 20 most in-
tense ions with multiple charged ions above a threshold ion count of 5000 were
selected for fragmentation at normalized collision energy of 35%. Fragment ion
spectra produced via collision- induced dissociation (CID) were acquired in the
linear ion trap, AGC was set to 5e4, isolation window of 2.0 m/z, and activation
time of 0.1 ms, and maximum injection time of 100 ms was used. All data were
acquired with Xcalibur software v2.2.
Acquired data were analyzed using the Proteome Discoverer software suite
(v1.3.0.339, Thermo Fisher Scientific), and the Mascot search engine (v2.3, Ma-
trix Science) was used for peptide identification. Data were searched against an
in-house generated database containing all proteins corresponding to human in
the Swissprot human database (as of 3/2013) with 600 added common contam-
inants, with a total number of 37,694 sequences in the database. A precursor
ion mass tolerance of 7 ppm at the MS1 level was used, and up to three miscle-
avages for trypsin were allowed. The fragment ion mass tolerance was set to
0.5 Da. Oxidation of methionine and protein acetylation at the N-terminal was
defined as variable modification. Carbamidomethylation on cysteines was set
as a fix modification. The identified peptides were filtered using a FDR less than
5%. Peptide areas (obtained with Proteome Discoverer) were used for protein
quantitation (Mascot decoy option activated).
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Selection of target proteins, their peptides and transitions. Approximately
100 out of the 490 proteins had at least 1 hi-flyer peptide identified in the dis-
covery scan. The Skyline analysis software was used to create spectral libraries
and predict optimal collision energy, retention times, and transitions for these
candidates.
Label-free selected reaction monitoring measurements
Optimization of Retention Times with Unscheduled Assays. Cleaned and
unfractionated peptides were analyzed with a triple quadrupole mass spec-
trometer (AB SCIEX) run in unscheduled mode with retention time peptides
to establish elution times. Peptides with high coefficients of variation across
technical replicates were triaged.
Label-free quantitation of target proteins with scheduled assays. Having
optimized elution times during unscheduled assay development, cleaned and
unfractionated peptides for samples were run in scheduled mode on a triple
quadrupole mass spectrometer (AB SCIEX). Approximately one-third of sam-
ples were run in biological triplicate, another one-third in biological duplicate,
and the remainder one biological replicate was chosen randomly. Multiple tech-
nical replicates were also performed. Peptide quantitation was performed using
Skyline software.
Data summarization (peptide-level to protein-level) and normalization (log2
drug:vehicle control. The R package MSstats v2.3.5 was used to explore the
data, summarize multiple biological and technical replicates at the peptide-
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level data to protein-level, and normalize drug treatment to vehicle treatment
[Choi et al., 2014]. MSstats fits a mixed-effects linear model that partitions the
variance in protein intensity into technical, biological, and experimental compo-
nents [Clough et al., 2012]. To perform summarization, the dataProcess function
was used with these arguments: logTrans = 2, normalization = constant, be-
tweenRunInterferenceScore = FALSE. To perform normalization and statistical
testing in comparison with DMSO vehicle treatment using the groupCompari-
sion function with arguments set as: labeled = FALSE, scopeOfBioReplication =
restricted, scopeOfTechReplication = expanded, interference = FALSE, feature-
Var = TRUE, missing.action = nointeraction. In each drug condition, I set log2
ratios to 0 for proteins that had adjusted p-values greater than 0.05, i.e., insuffi-
cient evidence to reject the null hypothesis that its intensity is not different from
drug vehicle.
Reverse-phase protein array measurements
note: these steps were performed by Xiaohong Jing in the Sander laboratory.
Cell pellets were thawed from -80°C to room temperature and lysed in CLB1 ly-
sis buffer (Bayer Technology Services). Protein concentrations were determined
by Pierce Coomassie Plus (Bradford) Assay Kit (LifeTechnologies). Protein con-
centrations were adjusted to 2 mg/ml in CLB1 lysis buffer and diluted 10x fur-
ther in CSBL1 spotting buffer (Bayer Technology Services). A four-fold dilution
series was prepared by the Biomek FXP Laboratory Automation Workstation
(Beckman Coulter) to protein concentrations of 0.2, 0.15, 0.1, and 0.05 mg/mL.
The dilution series was transferred to 384-well plates at 20 µL/well for spotting.
Samples were spotted onto tantalum pentoxide-coated glass chips (ZeptoChip,
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Bayer Technology Services) using the nano-plotter NP2.1 automatic pipetting
systems (GeSiM).
Distance from pin to chip, setting piezo, and other spotting parameters were
adjusted to achieve uniform, round, well-aligned spots. The piezoelectric tip
of the nano-plotter aspirated several nanoliters and then deposited single 400
pL droplets onto the glass slides. A reference solution of BSA was also spotted
adjacent to each dilution series. The spot layouts were not randomized and the
experimenter was not blinded to the experimental conditions. There were six
arrays per chip and each array was stained with one antibody or buffer control.
After spotting, chips were blocked for 20 minutes with an aerosol BSA solu-
tion using a customized blocking apparatus (ZeptoFog, Bayer Technology Ser-
vices). Chips were washed in double-distilled H2O and dried. Six spotted chips
were inserted in a carrier (ZeptoCarrier, Bayer Technology Services). Antibod-
ies were diluted in CAB1 following RPPA manufacturer recommendations. The
chips were incubated with primary antibodies for 24 hours followed by incu-
bation with a secondary antibody (Alex Fluor-647). Chips were washed with
CAB1 and imaged with fluorescence optometry (ZeptoREADER, Bayer Tech-
nology Services) in the red channel (excitation 635 nM, emission 675 nM).
For each array four separate images were acquired using automatic expo-
sure times from 1 to 10 seconds. Image analysis software (ZeptoView v.3.1)
selected the best exposure. Normalization for each spot was performed against
the BSA reference spots leading to a measurement of relative fluorescence in-
tensity (RFI). Each spot was rated ’good, poor, or indeterminate’ based on a
linear change in signal intensity across the dilution series. ’Poor’ and ’inde-
terminate’ quality spots were removed from subsequent analyses. Antibodies
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with a median intensity below 10x buffer control were considered noise and
removed from subsequent analysis. Remaining data was normalized by dou-
ble median normalization. In the first median pass, each antibody’s RFI values
were divided by the antibody’s median RFI in all conditions. In the 2nd median
pass, each condition’s antibody RFI values were divided by the median RFI in
the condition. The double-median normalized data were then summarized by
taking the mean of three biological replicates.
2.3 Network analysis methods, predictions, and assessment
2.3.1 Nominating novel drug combinations with network anal-
ysis
To retrieve protein-protein interactions from a database involving all of the pro-
teins measured by SRM and RPPA, antibody names had to first be mapped to
gene symbols. In several cases, the mapping is not one-to-one and all gene sym-
bols were retained. Phosphosites were given an edge to their corresponding
protein. Interactions were retrieved from a protein-protein interaction database
(Reactome, PathwayCommons2 v8) in simple interaction format. Proteins were
removed from the protein-protein interaction network that did not show evi-
dence of expression in the discovery phase data. To retrieve drug-protein inter-
actions for FDA-approved drugs, I downloaded the supplementary files from
Rask-Andersen et al [Rask-Andersen et al., 2011]. The statistical programming
language R was used to merge and analyze the protein-protein:protein-drug
network. For each perturbation I identified phosphosites and proteins with
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strong responses. I then checked whether there is an FDA approved drug target-
ing the responder or its nearest neighbor yielding a hit list. Network druggabil-
ity results were browsed visually using a network browser (Cytoscape v3.4.0). I
performed manual literature curation of the hit list to identify studies involving
the druggable nearest node and the drugs. I further filtered the results according
to whether the drug is easily obtained commercially. I chose the top-9 ranked
compounds for experimental testing. I estimated their IC50 doses in phenotypic
assays from the literature shown in table 2.1.
Responder Target Drug Dose Reference
STMN1 aurora kinase B barasertib 12.5 nM [Zekri et al., 2015]
pRB1 CDK1/2/5 dinaciclib 50 nM [Booher et al., 2014]
KLK3 PRKDC enzastaurin 1.5 µM [Graff et al., 2005]
YWHAZ MAPK losmapimod 10 nM [Triantaphyllopoulos et al., 2010]
EIF4E STAT3 napabucasin 1.5 µM [Zhang et al., 2016]
KLK3 HDAC panobinostat 5 nM [Anne et al., 2013]
CDH1 SRC saracatinib 500 nM [Chang et al., 2008]
AIP CSKN1A silmitasertib 2.5 µM [Ryu et al., 2012]
RHOA ERK1/2 ulixertinib 100 nM [Ward et al., 2015]
Table 2.1: Top-ranked predictions from druggable, nearest-responder-
node analysis. References are given for the target or the drug. Doses are
reported or estimated IC50 values from phenotypic assays.
2.3.2 Methods for testing network analysis predictions with
phenotypic measurements of cell death
To test network analysis predictions, I assayed four of the original drug set (do-
cetaxel, enzalutamide, MK2206, and temsirolimus) in all one-, two-, and three-
drug combinations with the top-9 hits in the prediction drug set (barasertib,
dinaciclib, enzastaurin, losmapimod, napabucasin, panobinostat, saracatinib,
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silmitasertib, ulixertinib). To measure drug effects on cell death, LNCaP cells
were seeded in 96-well plastic bottom plates at 12,500 cells per well in five bio-
logical replicates for all conditions. Cells were left at room temperature for 20
minutes for even seeding and placed in an incubator overnight. Drugs were ad-
ministered concurrently at half the estimated IC50 value for all one-, two-, and
three-drug combinations involving all one- and two-drug combinations of the
original drug set: docetaxel 5 nM, enzalutamide 5 µM, MK2206 0.5 µM, tem-
sirolimus 50 nM; with the prediction drug set: barasertib 12.5 nM, dinaciclib 50
nM, enzastaurin 1.5 µM, losmapimod 10 nM, napabucasin 1.5 µM, panobino-
stat 5 nM, saracatinib 500 nM, silmitasertib 2.5 µM, ulixertinib 100 nM. Drugs
were used at the same concentration for all one-, two- and three-drug combi-
nations. Drug dilutions were prepared such that the same volume of DMSO is
added for each treatment and DMSO vehicle control. Five biological replicates
were performed for each condition. The plate layouts were not randomized and
the experimenter was not blinded to the experimental conditions to minimize
confusion during manual labeling and pipetting.
To measure cell death, I used a reagent that fluoresces green when mem-
brane integrity is lost (CellTox Green, Promega). Fluorescence readings were
performed in a plate-reader (SpectraMax Gemini EM, Molecular Devices). Mea-
surements were acquired at time 0 and 2 days after drug addition with these
plate-reader settings: read mode: fluorescence top read; wavelengths: Ex 485,
Em 530, auto-cutoff off; sensitivity: 30 readings per well, PMT auto; automix:
60 sec before read; auto-calibrate on; column wavelength priority: column pri-
ority. Instrument software (SoftMaxPro v5.4.1) was used to acquire and export
data, which was further analyzed in R. Data were normalized by subtracting
the time 0 background intensity for each well and summarized across five bi-
20
ological replicate wells by computing the mean and standard error. Further
summarization was performed by comparison with drug vehicle DMSO.
2.3.3 Methods for testing network analysis predictions with
molecular measurements by discovery proteomics
LNCaP prostate cancer cells (approximately 3 million) were harvested follow-
ing drug treatments and resuspended in 800 µL of lysis buffer (8 M urea, 0.2%
RapiGest, 0.1 M ammonium bicarbonate), vortexed for 10 s, and shaken at 1000
rpm at room temperature for 10 min. Samples were sonicated (amplitude 90%,
cycle 0.6) for 2 x 2 min at 4°C and centrifuged at 13,200 rpm for 10 min. The clear
lysate was transferred to a new tube, the amount of protein was determined us-
ing the BCA assay (Pierce, Thermo Scientific), and the protein concentration
was diluted to 5 mg/mL with lysis buffer. The sample was reduced using
TCEP (tris-2-carboxyethylphophine) and alkylated using iodoacetamide, and
unreacted iodoacetamide was then neutralized with N-acetyl-cystein. The sam-
ples were then diluted with 0.1 M ammonium bicarbonate and 0.2% RapiGest
to a final concentration of less than 2 M urea. Proteins were digested at a basic
pH of 8.0 to 8.5 using sequence-grade modified trypsin (Promega) at a ratio of
1:100 for 14 h at 37°C. Digestion was stopped by decreasing the pH to less than
2 with formic acid. Samples were shaken another 30 min at 500 rpm at 37°C,
followed by centrifugation at 13,200 rpm for 10 min to remove any insoluble
fractions. Samples were cleaned with C18 columns.
Each sample was analyzed by LC MS/MS in an Orbitrip LTQ Velos mass
spectrometer (Thermo Fisher Scientific, San Jose, CA) coupled to nano-LC
21
(Proxeon, Odense, Denmark) equipped with a equipped with a reversed-phase
chromatography 12-cm column with an inner diameter of 75 m, packed with 5
m C18 particles (Nikkyo Technos, Japan). Chromatographic gradients started
at 97% buffer A and 3% buffer B with a flow rate of 300 nL/min and gradually
increased to 93% buffer A and 7% buffer B in 1 min and to 65% bufferA and
35% buffer B in 60 minutes. After each analysis, the column was washed for
10 min with 10% buffer A and 90% buffer (Buffer A: 0.1% formic acid in water;
Buffer B: 0.1% formic acid in acetonitrile). The mass spectrometer was operated
in positive ionization mode with nanospray voltage set at 2.2 kV and source
temperature at 250 C. Ultramark 1621 for the FT mass analyzer was used for ex-
ternal calibration prior the analyses. Moreover, an internal calibration was also
performed using the background poly- siloxane ion signal at m/z 445.1200.
The instrument was operated in DDA mode and full MS scans with 1 mi-
croscan at resolution of 60,000 were used over a mass range of m/z 2502000
with detection in the Orbitrap. Auto gain control (AGC) was set to 1e6, dy-
namic exclusion (60 s with a repeat duration of 30 s [repeat count = 1], and
an exclusion list size of 500 ions), and the charge state filter disqualifying singly
charged peptides was activated. Following each survey scan, the top 20 most in-
tense ions with multiple charged ions above a threshold ion count of 5000 were
selected for fragmentation at normalized collision energy of 35%. Fragment ion
spectra produced via collision- induced dissociation (CID) were acquired in the
linear ion trap, AGC was set to 5e4, isolation window of 2.0 m/z, and activation
time of 0.1 ms, and maximum injection time of 100 ms was used. All data were
acquired with Xcalibur software v2.2.
Acquired data were analyzed using the Proteome Discoverer software suite
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(v1.3.0.339, Thermo Fisher Scientific), and the Mascot search engine (v2.3, Ma-
trix Science) was used for peptide identification. Data were searched against an
in-house generated database containing all proteins corresponding to human in
the Swissprot human database (as of 3/2013) with 600 added common contam-
inants, with a total number of 37,694 sequences in the database. A precursor
ion mass tolerance of 7 ppm at the MS1 level was used, and up to three mis-
cleavages for trypsin were allowed. The fragment ion mass tolerance was set
to 0.5 Da. Oxidation of methionine and protein acetylation at the N-terminal
was defined as variable modification. Carbamidomethylation on cysteines was
set as a fix modification. The identified peptides were filtered using a FDR less
than 5%. Peptide areas (obtained with Proteome Discoverer) were used for pro-
tein quantitation (Mascot decoy option activated). Analysis of enriched path-
ways was performed using the GSA geneset analysis method, which uses the
maxmean statistic to compute an enrichment score for collections of gene sets
[Efron and Tibshirani, 2007]. Here the Reactome genesets were used.
23
CHAPTER 3
RESULTS - QUANTIFYING MOLECULAR AND PHENOTYPIC
RESPONSES TO DRUG PERTURBATIONS
3.1 Establishment of SRM assays
An initial protein list of interest in prostate cancer (PLIPCa) consisting of 490
candidates was developed through manual literature curation. These proteins
proved to be challenging targets. The top left panel of figure 3.1 compares the
abundances of all proteins detected in LNCaP by discovery MS following ex-
tensive offline fractionation in Geiger et al. [Geiger et al., 2012] against those de-
tected in our discovery MS from strong cation exchange fractionation and those
within the candidate list of 490 proteins. The result of this comparison is that the
majority of the 490 list are undetectable in all datasets; moreover, those that are
detected are highly enriched for low abundant proteins. The left bottom panel
shows that most proteins in the final target list were detected in either the strong
cation exchange or isoelectric focusing fractions, with a few peptides originat-
ing from unfractionated shotgun discovery scans or from a peptide database of
hi-fliers [Kusebauch et al., 2016]. The middle panel of figure 3.1 shows elution
times and transitions for several examples in the target list. The right panel
shows that our selection of the 24 hour time point is reasonable.
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Figure 3.1: SRM assay development and exploratory perturbation for
time point selection.
Left panel. Violin plot showing protein abundance distribution of proteins
quantified in LNCaP cells from Geiger et al., this study and estimated
abundance values of the target PLIPCa list. Circular Interaction Graph
for Proteomics representing the origin of all peptides corresponding to the
target PLIPCa proteins.
Middle panel. SRM assay development. Top row showing sum of tran-
sitions per peptide for three proteins (AR, KLK3 and CYC). Endogenous
peptides co-elute with stable isotope labelled reference peptides. Bottom
row showing individual transitions per peptide which are base line sepa-
rated.
Right panel. Time point selection. Top: six drugs were chosen and au-
tomated fluorescent microscopy quantified for apoptosis as a function of
time. Different drugs appear to trigger apoptosis with varying kinetics.
Therefore, our choice of the 24 hour timepoint is arbitrary and misses the
peak signal for many conditions. Bottom: the proteome of LNCaP cells
treated with enzalutamide was quantified at 0.5, 6 and 24 h post treatment.
The relative abundance changes for four proteins are shown.
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3.2 Phenotypic and proteomic responses to perturbations
Targeted proteomics measurements included 52 proteins measured by SRM and
70 (phospho)-proteins measured by RPPA quantified across 6 one-drug and the
15 possible two-drug combinations, plus a drug vehicle control. Data summa-
rized across biological and technical replicates and summarized as log2 ratio to
drug vehicle is show in figure 3.2. Most protein levels do not increase or de-
crease very much following drug perturbation. Some (phospho)-proteins are
consistently increased or decreased relative to drug vehicle, such as YWHAE,
YWHAB, and PAK1. Proteins showing relatively high variation among drug
conditions include pRB, EIF4E, and ACTR2. Measurements of pAKT in AKTi
conditions confirm known drug effects. The SRC inhibitor dasatinib has notice-
ably weaker effects on (phospho)-protein levels than other drugs at the doses
assayed.
3.3 Network analysis and predictions
A simple, binary network analysis method shown in figure 3.3 was used to iden-
tify candidate markers of response and resistance. For each drug condition, if
a (phospho)-protein increased or decreased twice that of vehicle treatment, it
was retained as a strong responder. These strong responders were mapped
onto a protein-protein-drug interaction network, where the drugs have been
filtered for commercial availability. Strong responders with druggable nearest
neighbors are nominated to enhance or counteract mechanisms of response or
resistance, respectively. In all cases, the strong responder was not located im-
mediately upstream or downstream of the drug target, but was located instead
26
B  (phospho)-Protein responses to one- and two-drug combinations
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A  Phenotypic responses to one- and two-drug combinations
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Figure 3.2: Phenotypic and proteomic responses to one- and two-drug
treatments.
(A) Phenotypic effects of one- and two-drug combinations administered
concurrently at single doses were assessed by microscopy. Drug names,
targets and doses are shown in Table 1. Drug effects were quantified by
percent area of viable cells, which is computed by subtracting the area of
fluorescence channel signal of the apoptosis probe (caspase 3/7 activation)
from the phase contrast channel measurement of cell area. Cells grew in
clumps that could not be segmented into individual cells for a compu-
tation of percent apoptotic cells. Comparing drug effects at day 5 (right
panel) to day 1 (left panel) reveals that effects are more pronounced and
more varied at day 5 than day 1. Error bars are +/- SEM.
(B) Integrated log2 responses of targets compared to vehicle 24 hours after
drug treatment. Proteins were measured by selected-reaction monitoring
mass spectrometry (SRM) and additional (phospho)-proteins were mea-
sured by reverse-phase protein arrays (RPPA).
27
in a parallel pathway. It is possible that greater coverage of signaling pathways
through additional SRM or RPPA targets might lead serial pathway inhibition
strategies.
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A  Network analysis and predictions of new combination therapies
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1  map drug responses
onto network database
2  Find responder subnetworks
and nearest druggable neighbors
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Subnetwork response of pRB to ARi (enzalutamide)
reveals combination treatment strategies including
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Figure 3.3: Network analysis of drug treatment responses identifies po-
tential network vulnerabilities and new drug combination strategies.
(A) The analysis method has three steps: (1) drug response data are
mapped onto a database network of protein-protein and protein-drug in-
teractions from PathwayCommons.org; (2) nearest-neighbor subnetworks
around proteins with strong responses to perturbations are extracted for
visualization and further analysis; (3) an additional filter is applied for
commercial availability and the extent of literature on the role of the target
and/or efficacy of the drug in prostate cancer because there are typically
numerous options for drugging the nearest node to a (phospho)-protein
with strong responses.
(B) Phospho-RB has strong responses to numerous perturbations includ-
ing AR inhibition with enzalutamide. This subnetwork shows that there
are no available drugs for targeting pRB directly but several options for
drugging its nearest neighbors.
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CHAPTER 4
RESULTS & DISCUSSION - STRATEGY 1: CO-TARGETING PI3K
SIGNALING AND CELL CYCLE
4.1 Testing predictions uncovers a PI3K signaling & cell cycle
inhibition strategy
To test network analysis predictions I assayed four of the original drug set
(docetaxel, enzalutamide, MK2206, and temsirolimus) in all one-, two-, and
three-drug combinations with the top-10 predictions from network analysis:
(barasertib, BV02, dinaciclib, enzastaurin, losmapimod, napabucasin, panobi-
nostat, saracatinib, silmitasertib, ulixertinib). Drugs were administered concur-
rently at half the estimated IC50 value for all one-, two-, and three-drug combi-
nations involving all one- and two-drug combinations of the original drug set.
To measure cell death I used a reagent that fluoresces green when membrane
integrity is lost. Only CDK1/2 inhibitor dinaciclib yielded effective two- and
three-drug combinations, shown in figure 4.1.
4.2 Discussion on PI3K signaling & cell cycle inhibition strat-
egy
Cell cycle inhibitors are considered a promising strategy for many cancers
[Lapenna and Giordano, 2009]. Stice and colleagues propose CDK4/6 in-
hibitors as alternatives to taxane therapy for prostate cancer [Stice et al., 2017].
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Figure 4.1: Testing network analysis predictions of the efficacy of CDK
inhibition in a cell death assay. The CDK1/2/5 inhibitor dinaciclib was
tested in all one-, two-, and three-drug combinations co-administered at
single doses with 4 members of the first drug set: docetaxel (microtu-
ble inhibitor), enzalutamide (AR inhibitor), MK2206 (AKT inhibitor), and
temsirolimus. Cell death was assessed after 48 hours of drug treatments.
Doses are given in Table 2. Dinaciclib is most effective in combination with
MK2206 and MK2206 with temsirolimus. Dinaciclib is relatively effective
on its own. Error bars are +/- SEM. Nine additional drug predictions from
network analysis were assayed similarly in all one-, two-, and three-drug
combinations but seven did not show efficacy at the dose tested and for
two drugs effects could not be determined.
Recent studies in prostate cancer biology have found that CDK5 acts as a crit-
ical signaling hub driving AR and AKT signaling, releasing cell cycle breaks
[Lindqvist et al., 2015]. A similar study found CDK5 regulates both STAT3 and
AR [Hsu et al., 2013]. In a review article, Balk and Knudsen describe feedback
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loops operating between AR, mTOR and cell cycle proteins, which are illus-
trated in figure 4.2 [Balk, 2007]. Gao et al. also reviewed the literature and
concluded similar connectivity between mTOR and cell cycle progression at the
G1/S transition [Gao et al., 2016].
Dinaciclib is a highly selective and potent inhibitor of CDK1/2/5
[Paruch et al., 2010]. It has been found to synergize with AKT inhibitor MK2206
in pancreatic cancer [Hu et al., 2015] and AKT inhibitors in ovarian cancer
[Au-Yeung et al., 2017]. In figure 4.2, I propose a highly simplified model where
dinaciclib enhances the cell cycle arrest response caused by AR inhibition with
enzalutamide and AKT inhibition with MK2206. This can be considered a serial
pathway inhibition strategy because blocking mTOR via AKT lowers CDK4/6-
mediated G1/S progression and dinaciclib blocks S/G2 and G2/M progression
by inhibiting CDK2 and CDK1, respectively. Additional experiments measur-
ing cell cycle status and (phospho)-protein status of RB, CDK4/5, CDK1, and
CDK2 are necessary to test the hypothetical mechanism in figure 4.2.
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Figure 4.2: Combined inhibition of AKT and cell cycle is more effective
than either drug alone. Following single drug treatment with PI3K path-
way inhibitors network analysis of targeted proteomics measurements of
drug responses led to the hypothesis that augmenting the response of
phospho-RB by inhibition of CDK1/2 would enhance drug efficacy. Single
drug efficacy may be limited by a feedback loop operating between MTOR
and PI3K or between AR and CDK4. A drug targeting CDK1/2 (dinaci-
clib DIN) was chosen based upon commercial availability, status in clinical
trials, and potency. A cell death assay confirmed the prediction. This inhi-
bition strategy is similar to serial pathway inhibition, however, the effects
are probably more complicated because of the many interactions among
these and other cell cycle proteins not shown.
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CHAPTER 5
RESULTS & DISCUSSION - STRATEGY 2: CO-TARGETING 14-3-3
PROTEINS IN COMBINATION WITH AKT AND AR
5.1 Testing predictions uncovers a 14-3-3 PI3K, and AR inhibi-
tion strategy
During network analysis I observed that 14-3-3 paralogs YWHAB, YWHAE,
and YWHAZ increased following the majority of drug perturbations. Quali-
tative network analysis predicted that 14-3-3 protein increases might be gen-
eral mechanisms of resistance to drug perturbation. My interest in testing this
prediction was augmented when I noticed that 14-3-3-zeta (YWHAZ) was re-
currently amplified in 27% of metastatic tumors shown in figure 5.2. To test
network analysis predictions, I assayed two of the initial drugs that have the
most recurrent alterations in metastatic tumors: AR inhibitor enzalutamide and
AKT inhibitor MK2206 with 14-3-3 inhibitor BV02. Drugs were administered
concurrently at the estimated IC50 value BV02, 10 µM enzalutamide, and 500
nM MK2006 in combinations: BV02 alone, BV02 + MK2206, BV02 + enzalu-
tamide, and BV02 + MK2206 + enzalutamide. Cell proliferation was assessed
by a colorimetric endpoint assay using tetrazolium dye MTT, which is con-
verted to formazan by oxidoreductase enzymes in metabolically active cells
[van Meerloo et al., 2011]. I also performed discovery proteomics on each per-
turbation condition using an orbitrap mass spectrometer to measure the molec-
ular effects of drug perturbation.
Analysis of drug response phenotypes revealed the triple combination of
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ARi+AKTi+YWHAZi to effect numerous proteins, including many from the tar-
get list shown in figure 5.3, with DNA-repair protein BRCA1 and transcription
factor NKX3.1 showing large decreases compared to drug vehicle. Geneset anal-
ysis identified decreases in multiple pathways relating to cell cycle and DNA re-
pair shown in figure 5.4. In the phenotypic assay of cell proliferation, the triple
combination showed increased efficacy over the one- and two-drug combina-
tions tested, shown in figure 5.5. These experiments are preliminary because
not all one- and two-drug combinations of the drugs were assayed. In partic-
ular, without measurements made for the AKTi+ARi combination, efficacy of
the triple combination of AKTi+ARi+YWHAZi may be less significant. Experi-
ments to measure all one- and two-drug combinations are being performed by
H. Alexander Ebhardt at his laboratory in University College, Dublin.
5.2 Discussion on 14-3-3, PI3K, and AR inhibition strategy
Molecular and phenotypic evidence indicates that triple inibition of 14-3-3,
PI3K and AR is a promising strategy. Drug response data in figure 5.4 indi-
cate that the triple combination appears to lower DNA repair genes suggesting
that AR activity is lowered because AR has been shown to coordinate DNA re-
pair and radioresistance [Polkinghorn et al., 2013]. Moreover, figure 5.5A shows
the the triple combination lowers expression of FKBP5, an AR target gene
that mediates reciprocal feedback inhibition between PI3K and AR pathways
[Carver et al., 2011]. Interestingly this pattern is reversed in PC3; however, com-
bined levels of 14-3-3 are low in both cell lines (figure 5.5A). These results pro-
vide a number of reasons for continued evaluation of the role of 14-3-3 proteins
in prostate cancer and their potential as drug targets.
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Figure 5.1: Patterns of protein responses across perturbations identify
consistent strong responders.
I. Proteins frequently quantified in prostate cancer (e.g. KLK3 [PSA] or
HSP90) show relatively small changes across pharmacologically perturbed
conditions.
II. Proteins consistently decreasing as a function of perturbation. PAK1
and HN1 have not been shown to be important for prostate cancer.
III. Proteins with consistent increases following drug perturbation include
14-3-3 proteins.
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The seven paralogous 14-3-3 proteins in humans have been considered as
potential therapeutic targets [Zhao et al., 2011]. 14-3-3 proteins are highly con-
served and recognize phospho-serine binding motifs RSXpSXP (mode 1) and
RXY/FXpSXP (mode 2) [Fu et al., 2000, Aitken, 2006]. They interact with more
than 100 proteins and play regulatory roles including alteration of enzymatic
activity, alteration of DNA-binding activity, sequestration, altering protein-
protein interactions, and adaptor protein functions [Hermeking, 2003]. In par-
ticular their roles in inhibiting apoptosis makes them of interest as therapeutic
targets [Hermeking, 2003, Aghazadeh and Papadopoulos, 2016].
In prostate cancer, 14-3-3 protein YWHAZ was shown by Menon and col-
leagues to be amplified in 48% of CRPC patients and knockdown reduced pro-
liferation and migration in vitro [Menon et al., 2013]. In addition to 14-3-3 pro-
teins’ roles in inhibiting apoptosis, Oh and colleagues found that non-sigma
14-3-3 proteins protect ETV1 from degradation, thereby promoting prostate tu-
morigenesis [Oh et al., 2013]. Ruenauver and colleagues examined the prognos-
tic significance of YWHAZ and found high expression is associated with high
gleason score, higher risk of CRPC development, and reduced survival time
[Ru¨enauver et al., 2014].
During our investigation of YWHAZ in prostate cancer I realized that
it is located on 8q, which is a recurrent whole-arm chromosomal amplifi-
cation in prostate cancer and has prognostic significance [Silva et al., 2016].
cMYC is considered a driver on 8q and additional genes have been shown to
play roles including AR-coactivator NCOA2 and YWHAZ [Silva et al., 2016,
Menon et al., 2013]. Intriguingly, I also observe recurrent co-occurrence of
nMYC and YWHAQ amplification on 2p (figure 5.5B). Our result that triple
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combination AKTi+ARi+YWHAZi causes decreases in cell cycle and DNA re-
pair proteins suggests an inhibition of AR activity because AR is known to mas-
ter regulate DNA repair [Polkinghorn et al., 2013]. This evidence from the lit-
erature taken together with our preliminary findings that YWHAZ may play
a role in resistance mechanisms to drug treatment are plausible and warrant
further investigation. Inhibitor BV02 was developed as a c-Abl and 14-3-3σ in-
hibitor and its specificity for the other paralogs is unclear [Mancini et al., 2011],
so siRNA experiments are currently being performed by H. Alexander Ebhardt
at his laboratory at University College, Dublin.
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Figure 5.2: Recurrent alterations in primary and metastatic tumors show
amplifications in 14-3-3 protein YWHAZ.
(A) Oncoprint of primary prostate tumor data shows recurrent alterations
in PTEN and FOXO1.
(B) Oncoprint of metastatic prostate tumor patient data shows recurrent
amplifications in AR and YWHAZ. [Created with cBioPortal for cancer
genomics [Cerami et al., 2012]] 39
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Figure 5.3: Effects on relative protein expression of 14-3-3 inhibitor BV02
for proteins in the target list.
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Figure 5.4: Geneset analysis of triple combination therapy of ARi, AKTi,
and YWHAZi indicates decreases in DNA repair and other processes.
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Figure 5.5: Combination therapy targeting YWHAZ, AKT and AR and
patient alterations in YWHAZ.
(A) Molecular and phenotypic effects of YWHAZ inhibitor BV02
(B) YWHAZ amplifications co-occur with MYC on 8q or 2p. [Created with
cBioPortal for cancer genomics [Cerami et al., 2012]]
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CHAPTER 6
ALTERNATIVE APPROACH: IDENTIFYING ANDROGEN RECEPTOR
INTERACTING PROTEINS
6.1 Introduction - AR-interacting proteins may be good drug
targets
AR signaling is necessary for prostate tumorigenesis and its blockade by andro-
gen deprivation therapy results in the emergence of castrate resistance, that is
treated by second line blockade with AR and CYP17A1 inhibitors to which resis-
tance again emerges [Spratt et al., 2016]. Given this importance of AR I sought
to understand how co-activators, co-repressors, and other interactors influence
its signaling in prostate cancer.
AR-interacting proteins have been previously identified in several stud-
ies. Jasavala and colleagues used the 293 human embryonic kidney cell
line to identify interactors in cytosolic and nuclear fractions using AP-MS
[Jasavala et al., 2007]. Norris and colleagues used a high-throughput T7 phage
display to identify ligand-bound interactors [Norris et al., 2009]. The effect of
AR mutations WT, T877A, and 0CAG on interactors was examined in mon-
key kidney fibroblast-like COS-1 cells following mibolerone using his-tagged
AP-MS [Paliouras et al., 2011]. A variation of this approach developed an N-
TAP-mAR in engineered P17 and M7 mouse epidydimal cells and showed
loss of only a few interactors in the tagged version in proliferating (37°C) and
nonproliferating (33°C) conditions in nuclear and cytosolic fractions by AP-
MS [Mooslehner et al., 2012]. Effects of the T877A mutations were also exam-
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ined in LNCaP cells under eight treatment conditions (dihydrotestosterone,
mibolerone, R1881, testosterone, estradiol, progesterone, dexamethasone, and
cyproterone acetate) by AP-MS and differences in interactors were shown
to have prognostic value for survival in patient cohorts [Zaman et al., 2014].
AR interactors are also catalogued in databases, e.g., PathwayCommons.org
[Cerami et al., 2011]. Despite these resources, there is a gap in our understand-
ing of how clinically-relevant perturbations such as enzalutamide treatment af-
fect AR interactors in prostate cancer.
I aimed to identify AR interactors in the VCaP cell line following pertur-
bation with AR ligand DHT, agonist bicalutamide, antagonist enzalutamide,
and drug vehicle DMSO [Tran et al., 2009]. I chose VCaP because it has rela-
tively high expression of AR protein [van Bokhoven et al., 2003]. Our experi-
mental design included subcellular fractionation to identify interactors in cy-
tosolic and nuclear-enriched fractions because AR shuttles between cytoplasm
and nucleus upon activation and its translocation is affected by enzalutamide
[Tran et al., 2009]. One approach to identifying protein interactors is affinity-
purification mass spectrometry (AP-MS) [Gstaiger and Aebersold, 2009]. By
quantifying ”interactomes”, AP-MS has made important contributions to net-
work biology, including metabolism [Rouleau et al., 2017] and nuclear receptor
studies including the estrogen receptor [Mohammed et al., 2013].
Our AP-MS workflow is shown in figure 6.1. There are a variety of meth-
ods for performing affinity-purification, e.g., FLAG-tagging and I chose to use
a polyclonal antibody against the N-terminal region, shown in figure 6.1. All
affinity-purification methods have the potential to disrupt protein-protein in-
teractions. By choosing an antibody that recognizes an epitope within the first
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50 amino acids at the N-terminus this issue may be minimized, see figure 6.1B.
After identifying AR interactors I will analyze how they compare to known AR
interactors in databases, how they change with ligand, agonist, and antagonist
perturbations, and how they are recurrently altered in patient cohorts, see figure
6.1A.
6.2 Methods - identification of AR-interacting proteins in a cel-
lular context relevant to prostate cancer with AP-MS
note: Wetlab experiments were performed by Wassim Abida in the Sawyers laboratory
and proteomics by H. Alexander Ebhardt in the Aebersold laboratory. I analyzed the
data and created the figures. Appendix B describes authorship in more detail.
6.2.1 Cell culture and drug treatments
The VCaP cell line is AR sensitive and was isolated from a vertebral bone
metastasis from a patient with CRPC [van Bokhoven et al., 2003]. Cultures were
maintained in a humid 5% CO2 atmosphere at 37°C and grown in DMEM
medium supplemented with 10% heat-inactivated fetal bovine serum, 100
units/ml each of penicillin and streptomycin, and 2mM L-glutamine. Cells were
treated with 1nM DHT, 10µM bicalutamide, 10µM enzalutamide, and DMSO for
2 hours.
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Figure 6.1: Identification of AR-interacting proteins after ligand, ago-
nist, and antagonist treatment by affinity purification mass spectrome-
try (AP-MS).
(A) The prostate cancer cell line VCaP is an early metastatic model that
expresses full-length AR and is sensitive to its inhibition. VCaP cells
were grown in normal culture media and treated with ligand dihydroxy-
testosterone (DHT), agonist bicalutamide (BICA), and antagonist enzalu-
tamide (ENZA). Cells were lysed and fractionated into cytoplasmic- and
nuclear-enriched. A polyclonal antibody recognizing the N-terminal do-
main of AR immunoprecipitated interacting proteins. Analysis by mass
spectrometry revealed a number of proteins differentially abundant across
treatments. Additional analyses integrating databases of AR-interacting
proteins, recurrent alterations in prostate cancer patients, and druggabil-
ity prioritized interactors for additional experimentation.
(B) Domain structure of full-length androgen receptor including the N-
terminal domain (NTD), DNA-binding domain (DBD), hinge, and ligand-
binding domain (LBD). The LBD is thought to be the site of drug bind-
ing. The antibody used for pull-down is Santa Cruz N20 binds in the first
50 amino acids potentially disrupting some protein-protein interactions.
Other methods, such as FLAG- or HIS-tags would also suffer from this
problem.
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6.2.2 Affinity Purification Mass Spectrometry
AP-MS methods follow Hauri and colleagues with some modifications
[Hauri et al., 2013]. Cells were collected, frozen in liquid nitrogen and stored
at 80°C prior to protein complex purification. The frozen cell pellets were re-
suspended in 4 ml lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 50 mM
NaF, 0.5% Igepal CA-630 (Nonidet P-40 Substitute), 200 mM sodium orthovan-
odate, 1 mM phenylmethane sulfonylfluoride, 20 mg/ml Avidin and 1x Pro-
tease Inhibitor mix (Sigma) and incubated on ice for 10 min. Insoluble material
was removed by centrifugation. Complexes were pulled down by immuno-
precipitation with the N20 anti-AR antibody (SantaCruz). IgG only served as a
negative control. Cysteine bonds were reduced in the dark with 5 mM TCEP for
30 min at 37°C and alkylated in 10 mM iodoacetamide for 30 minutes at room
temperature. Samples were diluted with ammonium bicarbonate to 1.5 M urea
and digested with 1 µg trypsin (Promega) overnight at 37°C. The peptides were
purified using C18 microspin columns (Nest Group) in 0.1% formic acid, 1%
acetonitrile.
Discovery mass spectrometry measurements were performed on an Orbi-
trap XL (Thermo Fisher Scientific). Peptide separation was performed by a
Proxeon EASY-nLC II liquid chromatography system (Thermo Fisher Scientific)
connected to an RP-HPLC column packed with Magic C18 AQ resin (WICOM
International). Solvent A was used as RP-HPLC stationary phase (0.1% formic
acid, 2% acetonitrile). Solvent B was used as the mobile phase (0.1% formic
acid, 98% acetonitrile). A linear gradient was run to elute the column from 5 to
35% over 60 min at a flow rate of 300 nl/min. Data acquisition was set for one
high resolution MS scan in the Orbitrap (60,000 @ 400 m/z). The 6 most abun-
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dant ions from the first scan were fragmented by collision- induced dissociation
(CID) and the linear trap quadrupole (LTQ) acquired the MS/MS fragment ions.
Charge state screening was enabled and unassigned or singly charged ions were
rejected. A dynamic exclusion window of 15 s was limited to 300 entries. MS
precursors had to exceed 150 ion counts for MS/MS scans. Accumulation time
of ions was set to 500 ms (MS 1) and 250 ms (MS 2) using a target setting of
106 (MS 1) and 104 (MS 2). A reference sample containing 200 fmol of human
Glu1-fibrinopeptide B (Sigma) was analyzed to monitor the LC- MS/MS sys-
tems performance after each batch.
Level 1 data spectra were analyzed with X!Tandem against the canonical
human proteome reference dataset, with reverse decoy sequences. The search
parameters were set to include only fully tryptic peptides (KR/P) containing up
to two missed cleavages. Carbamidomethyl on cysteines was set as a peptide
modification. Oxidation on methiones and phosphorylation on serines, thre-
onines, and tyrosines were set as peptide modifications. The precursor mass
tolerance was set to 25 ppm, the fragment mass error tolerance to 0.5 Da. Pep-
tides were statistically evaluated using PeptideProphet and protein inference by
ProteinProphet, both part of the Trans Proteomic Pipeline. A minimum protein
probability of 0.9 was set to match a false discovery rate (FDR) of less than 1%.
Level 2 data comparison of IgG pulldown with each treatment condition
was performed using the SAINT method [Choi et al., 2002] using the SAINTex-
press software [Teo et al., 2014]. Proteins below a corrected FDR of 10% in any
condition were retained and compared against commonly detected proteins in
AP-MS datasets (Crapome) [Mellacheruvu et al., 2013]. Databases of previously
identified AR interactors were compared with the AP-MS data from VCaP. Path-
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Figure 6.2: AR antibody pulls down complexes and negative control IgG
pull down does not.
(A) Western blot for AR following drug vehicle (V), ligand DHT (D), ag-
onist bicalutamide (B), and antagonist enzalutamide (E) for nuclear- and
cytoplasma-enriched fractions.
(B) ImmunoPrep of AR in the experiment shows reasonable efficiency us-
ing the N20 antibody. Control IgG is not pulling down AR.
wayCommons v8 [Cerami et al., 2011], stringDB v10 [Szklarczyk et al., 2015],
and McGill AR interactors database [Gottlieb, 1998].
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Figure 6.3: Silver stain of AR pull-downs following perturbations shows
numerous interactors but few changes across perturbations. There are
a few observable changes in bands across conditions but in general not
large differences among conditions, with the caveat that silver stain is not
always a particularly sensitive technique. (V) drug vehicle, (D) agonist
DHT, (B) bicalutamide, (M) antagonist MDV3100 or enzalutamide. The
negative control lane shows few bands as expected.
6.3 Results - identification of AR interactors and effects of drug
perturbations
I used an in vitro prostate cancer model of CRPC perturbed with clinically-
relevant drugs and identified proteins that interact with AR by AP-MS. Pull
down efficiency was assessed initially by western blot shown in figure 6.2,
which shows that IgG negative control is not pulling down AR and both enza-
lutamide and drug vehicle treatment results in lower nuclear AR than DHT and
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bicalutamide. A silver stain shows no massive differences among perturbation
conditions, shown in figure 6.3. I identified many previously reported AR in-
teractors including PRKDC, ARID1A, ARID1B, SMARCA4, SMARCC1, USP7,
and HSP90AA1/AB1. I also identified over 50 putative interactors that are un-
reported in the PathwayCommons database, including ERF, MTDH, CHTF8,
BAG2 and PGAM5.
A total of 111 proteins were quantified across four treatments, with 105 of
those proteins present in ligand DHT treatment or vehicle shown in figure 6.4.
Gene ontology molecular function categories were mapped to each protein us-
ing biomaRt. This resulted in more than 1,000 ontology categories that were
manually simplified into eight categories shown in figure 6.4B. Significantly
fewer interactors were identified in the cytoplasmic compared to the nuclear
fractions, figures 6.4A and 6.5. Approximately one-third of interactors con-
tained AR sequence recognition motifs LXXLL or FXXLF, figures 6.6 and 6.7.
I found minimal differences in AR interactions between agonist and antag-
onist treatment. Figure 6.8 shows a plot of mean spectral counts for enzalu-
tamide treatment vs DHT treatment. A number of proteins show differences
in their means; however, further examination of their variance or behavior in
drug vehicle treatment suggests that there is not a statistically significant differ-
ence, which was confirmed by unpaired t-test with multiple hypothesis testing
correction.
Many interactors are recurrently altered in more than 20% of patient cohorts
and may represent promising drug targets, see figure 6.9. Some interactors re-
currently altered in patient cohorts above 20%, including CHTF8 which shows a
pattern of loss in metastatic samples consistent with its known roles as a tumor
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Figure 6.4: AP-MS identifies numerous, diverse, and novel AR-
interacting proteins.
(A) Log2 of protein spectral counts for proteins with a Bayesian false-
discovery-rate less than 0.05 compared to IgG negative control as deter-
mined by SAINTexpress. Missing values shown in gray do not necessarily
indicate the absence of a proteins expression.
(B) Simplified ontology categories for the AP-MS proteins show a large
diversity in functions. GO categories for all the proteins were manually
simplified into eight categories.
(C) Overlap of AP-MS with known interactors reveals novel interactors.
AR interactors reported in several databases show limited agreement with
interactors found by AP-MS in VCaP. PathwayCommons (PC8) is a union
of public pathway databases; String (version 10) was limited to high con-
fidence, experimentally determined interactors; McGill is a manually cu-
rated database of AR interactors.
(D) Computationally predicted probability of AP-MS interactions deter-
mined by PrePPI method, which uses structural, functional, evolutionary,
and protein expression (Chen/Honig, PLoS Comp Bio 2015)
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Figure 6.5: Statistical assessment of differential expression between
negative control vs. perturbations. Peptide-to-protein summarization
and quantification of spectral counts is performed with the Transpro-
teomic Pipeline search engines. Statistical assessment comparing each per-
turbation condition against IgG pulldown was performed with SAINTex-
press. It computes a Bayesian false-discovery-rate (BFDR) for each pro-
tein, corrected for multiple hypothesis testing. Proteins with high spec-
tral counts are more likely to show statistically significant differences with
negative control IgG pull-down.
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Figure 6.6: Occurrences of AR-interaction motifs in interactors. Andro-
gen receptor is known to bind to LXXLL and FXXLF motifs. Approx-
imately 1/3 of the interactors identified by AP-MS contain at least 1 of
these motifs. PRKDC is an outlier containing numerous occurrences of
the LXXLL motif. Presence of either motif is evidence that an identified
interactor is less likely to be a false positive. For example, BAG2 and
CAM2KD are not reported as AR interactors in PathwayCommons, McGill
AR database, or StringDB but they each contain an LXXLL motif.
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Figure 6.7: Distribution and overlap of AR interaction motifs among
identified interactors.
suppressor. MTDH shows a pattern of amplification consistent with its known
roles in epitheial-to-mesenchymal transition.
6.4 Discussion
Using AP-MS and the VCaP model perturbed with clinically-relevant drugs I
identified a large number of AR interacting proteins that are previously unre-
ported and confirmed a number of well-known interactors including SWI/SNF,
PRKDC and chaperone proteins. AR interactors appear to be robust against
drug treatment with agonist bicalutamide or antagonist enzalutamide, suggest-
ing that interactomes may not be as dynamic as is sometimes described in the lit-
erature [Paliouras et al., 2011, Mohammed et al., 2013]. These results also raise
the possibility that although enzalutamide blocks some nuclear translocation
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Figure 6.8: AR-Interacting proteins are present in similar abundances
across ligand and antagonist treatments.
(A) Plot of ligand DHT vs antagonist enzalutamide shows most proteins
have similar expression levels in both treatments. Statistical analysis
with SAINTexpress indicated no statistically significant differences in ex-
pressed proteins across the treatment conditions. SAINTexpress incorpo-
rates spectral counts and percent of a proteins amino acid chain detected.
(B) Six proteins are shown for biological interest. Black dots indicate mea-
surements in 4 biological replicates. Blue dots indicate mean values and
blue lines indicate +/- 1.5 standard deviations. BAG2 promotes protein
release from the chaperone HSP70. CTNNA1 works in cell adhesion by
interacting with cadherins. GMPPB is thought to be involved in oligosac-
charide metabolism. PRKDC is a serine/threonine kinase that senses DNA
damage. SMARCE1 is part of the SWI/SNF complex and is involved in
chromatin modification. USP7 is a deubitquitinase.
of AR, this does not result in large effects on interactors [Tran et al., 2009]. It
is certainly also possible that there are large effects but the 2 hour time point
that I chose is too early. A time-course experiment to investigate this further
is warranted. It is also possible that affinity purification and subsequent sam-
ple processing lacks the requisite sensitivity to find differences in interacting
proteins.
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Figure 6.9: Recurrent alterations in AR-interacting proteins in large clin-
ical cohorts. Most AR interacting proteins are recurrently altered in less
than 20% of patient samples in primary and metastatic prostate cancer
at the levels of DNA mutations, copy number deletions/amplifications
and mRNA expression high/low. Data for primary prostate tumors comes
from a TCGA 2015 study with more than 300 patient samples. Metastatic
tumor data in Robinson et al., Cell 2015 (Michigan) has more than 100 pa-
tient samples. In metastatic tumors amplifications occur in metadherin
MTDH, which is known to activate NF-kappaB. [Created with cBioPortal
for cancer genomics [Cerami et al., 2012]]
Techniques such as FLAG-tagging or cross-linking could improve sensitiv-
ity. For example, Mohammed and colleagues used cross-linking to examine lig-
and (estrogen) vs antagonist (tamoxifen) effects on ER-protein interactions and
found large differences with GREB1 by SILAC ratio [Mohammed et al., 2013]. I
chose a label-free relative quantification strategy. It is possible that I could im-
prove sensitivity and decrease noise using label-based relative quantification,
such as SILAC or TMT [Ebhardt et al., 2015].
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AR interactors represent a category of potential targets for prostate cancer
drug development [Spratt et al., 2016]. Co-activator NCOA2 is recurrently am-
plified in 6% of CRPC patients and NCOA3 is a target of ubiquitin ligase SPOP
[Spratt et al., 2016]. Surpisingly, neither co-factor was identified here by AP-
MS, suggesting that the N20 antibody used for affinity purification may have
disrupted these interactions with AR. Metadherin (MTDH) is an interactor iden-
tified here that is also recurrently amplified in metastatic tumors and is known
to activate NF-kappaB and play roles in epithelial-to-mesenchymal transition.
Reciprocal pulldown experiments and genetic knockdowns are necessary ex-
periments to demonstrate that it both interacts with AR and that its knock-
down has consequences in phenotypic assays. Wei and colleagues demonstrate
that knockdown of MTDH effected viability, apoptosis, sensitivity to cisplatin
and migration in PC3, LNCaP and DU145 [Wei et al., 2015]. They also found
crosstalk with PI3K signaling [Wei et al., 2015].
The AP-MS experiments presented here identified unreported interactors,
confirmed known interactors, and suggest that drug perturbations may not
have much effect on AR interacting proteins. Metadherin was identified as a
previously unreported interactor that is recurrently altered in patient cohorts
and warrants further testing. Dynamic measurements of AR interacting pro-
teins using different experimental techniques are also warranted given the im-
portance of AR to prostate tumorigenesis and the possibility of blocking AR-
signaling by co-targeting multiple proteins with combination therapy.
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CHAPTER 7
CONCLUSION & FUTURE DIRECTIONS FOR PROSTATE CANCER
COMBINATION THERAPY
7.1 Targeted proteomics and perturbation biology are a promis-
ing approach to develop combination therapy
By using a perturbation biology approach with targeted proteomics and net-
work analysis, I was able to identify (phospho)-protein markers of response
and resistance to clinically-relevant drug perturbations after short-term expo-
sure. Proteomics measurements could be improved by incorporating labels for
relative quantitation, such as TMT or by using state-of-the-art parallel reaction
monitoring (PRM). Relatively simple network analysis led to the predictions
of more than 10 novel drug combinations. My hypothesis is that these com-
binations would either block resistance mechanisms or enhance drug potency.
A highly potent drug combination will reduce the cancer population numbers
and/or growth rate, thereby significantly lowering the probability of the emer-
gence of resistance.
Ten drugs were tested in all one-, two- and three-drug combinations with
AR, AKT, MTOR and taxane therapy using phenotypic assays and discovery
proteomics (14-3-3 inhibitor only) resulting in two promising drug combina-
tions that warrant further testing and eight that probably do not. The first
strategy is AKT inhibitor MK2206 + CDK1/2/5 inhibitor dinaciclib. This is a
somewhat novel result because although cell cycle inhibitors are currently be-
ing tested in clinical trials in prostate cancer, most inhibitors target CDK4/6 and
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not CDK1/2/5 [Spratt et al., 2016]. I am also confident in this strategy because
Hu and colleagues reported drug synergy with this combination and launched
an NCICTEP-approved multicenter phase I clinical trial in pancreatic cancer
[Hu et al., 2015].
The second combination strategy is AR inhibitor enzalutamide + AKT in-
hibitor MK2206 + 14-3-3 inhibitor BV02. This strategy shows molecular and
phenotypic evidence of efficacy. Moreover, there are recurrent alterations in
YWHAZ in patient cohorts with prognostic value. Due to concerns with the
specificity and efficacy of BV02, experiments are being planned with siRNA
knockdown and will be carried out by H. Alexander Ebhardt’s laboratory at
University College, Dublin. Further molecular and phenotypic measurements
at the preclinical level are warranted before pursuing either strategy in pa-
tients. In particular, xenograft or GEM experiments would be helpful to con-
firm efficacy of strategy I and II in vivo. Molecular measurements of (phospho)-
protein responses are also warranted including: phospho-RB to assess cell cy-
cle; phospho-AKT, phospho-p70S6K, phospho-4EPB1 to assess PI3K signaling
activity; AR target FKBP5 to assess AR activity; cleaved-PARP and cleaved-
caspase3/7 to assess apoptosis; ki67 to assess proliferation. If these preclinical
data are promising then discussions about whether to pursue clinical trials are
warranted.
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7.2 A diversity of approaches to develop combination therapy
should continue to be pursued
Developing combination therapy is a hard problem, partly because the search
space grows exponentially with each additional variable [Bulusu et al., 2016].
However, there are a number of recent advances in pre-clinical and clinical re-
search that give reasons for optimism. Recent work by Zimmer and colleagues
found that in vitro phenotypic drug effects in higher order drug combinations
could be predicted from only measurements of drug pairs [Zimmer et al., 2016].
There is a long and rich tradition in physics and biology of predicting
higher order effects from pairwise interactions, including the EVfold method
for predicting protein structure from co-evolution of amino-acid sequences
[Marks et al., 2011]. These findings suggest that pairwise screening of drug and
drug-like libraries in cancer cell line panels may enable successful prediction of
n-drug combinations. At the same time, advances in creating prostate organoids
and patient-derived xenograft models are enabling drug development, particu-
larly for prostate cancers that are not well-represented by the commonly used
cell lines LNCaP, VCaP, PC3, DU145 and 22Rv1 [Pauli et al., 2017].
In addition to advances in pre-clinical research for combination ther-
apy development, there has also been progress in our understanding of the
molecular alterations and tumor heterogeneity in prostate cancer patients
[Taylor et al., 2010, Chen et al., 2013, Boutros et al., 2015, Robinson et al., 2015,
Drake et al., 2016, Spratt et al., 2016, Blattner et al., 2017]. Combination ther-
apy including immuno-therapies may greatly augment drug combinations
[Fong et al., 2009]. Efforts to create shared databases that match molecu-
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lar alterations and germline DNA with drug sensitivity and toxicity pro-
files will help direct patients to clinical trials to enable personalized medicine
[Cerami et al., 2012, Huang et al., 2017] similar to what was achieved in HIV
but at a greater level of complexity [Bock and Lengauer, 2012]. International ef-
forts to coordinate sharing of clinical data will facilitate personalized medicine
[Vis et al., 2017, Siu et al., 2016].
Advances in molecular measurement technologies and economies of scale
now make it feasible to sequence prostate cancer genomes for both research
purposes and integration into clinical support systems [Pauli et al., 2017]. Ad-
vances in high resolution chromatography and mass spectrometry proteomics
are augmenting genomic information and providing information about cellular
signaling networks through measurements of regulatory modifications, such
as phosphorylation [Cifani et al., 2017, Mertins et al., 2016]. By integrating the
two, proteogenomics provides insights into DNA-to-RNA-to-protein regula-
tion, cellular signaling networks, disease subtypes, and biomarkers for diagno-
sis or treatment prediction [Ruggles et al., 2017, Nesvizhskii, 2014]. Large-scale
pharmaco-genomic studies aim to predict one-, two-, multi-drug sensitivities
from tumor genomes [Iorio et al., 2016]. The addition of proteomic measure-
ments will provide information about signaling and metabolic networks that
may lead to an emerging field of pharmaco-proteogenomics with even greater
ability to predict drug effects.
Early detection and biomarker development efforts, including hereditary
testing for DNA repair defects may improve patient stratification and treatment
outcomes [Evans et al., 2016]. Although the history of biomarker research is
plagued by failures [Ioannidis, 2013], there is new optimism that improvements
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in high resolution chromatography, mass spectrometry, circulating tumor DNA,
and a greater rigor in statistical methodologies and study designs may finally
discover new clinically useful biomarkers [Cifani et al., 2017, Skates et al., 2013].
In conclusion, there is a great diversity of approaches having success in prostate
cancer research that have only been briefly described here that are contributing
to developing effective combination therapies.
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Biological systems are composed of numerous components of which proteins are of particularly
high functional significance. Network models are useful abstractions for studying these com-
ponents in context. Network representations display molecules as nodes and their interactions
as edges. Because they are difficult to directly measure, functional edges are frequently inferred
from suitably structured datasets consisting of the accurate and consistent quantification of
network nodes under a multitude of perturbed conditions. For the precise quantification of
a finite list of proteins across a wide range of samples, targeted proteomics exemplified by
selected/multiple reaction monitoring (SRM, MRM) mass spectrometry has proven useful and
has been applied to a variety of questions in systems biology and clinical studies. Here, we
survey the literature of studies using SRM-MS in systems biology and clinical proteomics. Sys-
tems biology studies frequently examine fundamental questions in network biology, whereas
clinical studies frequently focus on biomarker discovery and validation in a variety of diseases
including cardiovascular disease and cancer. Targeted proteomics promises to advance our un-
derstanding of biological networks and the phenotypic significance of specific network states
and to advance biomarkers into clinical use.
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1 Introduction
1.1 Why networks?
Many observations related to signaling cascades and other
biological processes cannot be explained with a simple lin-
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itoring; QQQ, triple quadrupole
ear network model. This has led to the realization that the
components of biological systems are not simply connected
in a linear fashion but through a web of interactions, feed-
back loops, and crosstalk at multiple spatial and temporal
scales and prompted a shift towards considering these pro-
cesses as dynamic network. Models of such networks aim at
increasing our understanding how changes in network state
in specific contexts throughout normal development, disease,
and in response to perturbations [1–3] generate or modulate
phenotypes. A molecular network is an abstract construct
in which nodes represent molecules and the edges signify a
variety of physical or functional types of interactions. Physical
interactions include interactions between proteins, enzyme–
substrate relationships, transcription factors and their
target genes, and protein–RNA interactions. Functional in-
teractions include transient enzyme–substrate interactions,
genetic interactions7&N and other functional dependencies
of presently unknown mechanism. Because functional inter-
actions are difficult to directly measure they are frequently
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Figure 1. Network biology paradigm and complexities of proteomes. (A) Network biology paradigm. Protein–protein interactions can be
modeled as networks involving a variety of interaction types. (B) A few complexities of the proteome. Studying proteins is complicated
due to several factors: (i) a typical cell contains in excess of 20 000 different proteins, isoforms, and post-translational modifications
(PTMs); (ii) the range of absolute abundances spans more than seven orders of magnitude; (iii) each cell, tissue, and organism has a
different complement of proteins; (iv) proteins vary in space and (v) in time; (vi) proteins are involved in numerous interactions subject to
context-dependent “rewiring”.
inferred by statistical correlation from suitably structured,
large datasets [4–6]. Networks also provide a unifying con-
ceptual and mathematical framework for systems biology,
ecology, and neuroscience [7]. An example of a biological net-
work from the recent literature [8] is shown in Fig. 1. Along-
side conceptual advances, immense technological progress
now supports the identification and quantification of nucleic
acids, proteins, lipids, carbohydrates, metabolites, and small
molecules at sufficient coverage, depth, and throughput for
the study of biological networks in diverse contexts, such as
cell lines, body fluids, or tissues from various organisms and
across developmental stages or among phenotypic states [9].
1.2 Why proteins?
Proteins are key components of many types of molecular net-
works, performmost biochemical functions of the cell and are
the targets of most current drugs [10]. Although proteins can
be reliably identified by the well known discovery proteomics
methods at high throughput [11] and their 3D structures can
be determined experimentally or computationally [12], there
remain numerous unsolved problems relating to their struc-
ture and function in the context of network biology. Measur-
ing proteins poses technical challenges, particularly in higher
eukaryotes which are made-up of trillions of cells that are cat-
egorized, somewhat arbitrarily, into more than 400 different
cell types [13]. The two foremost challenges are the sheer
number of proteins present in a cell and their vast dynamic
range of expression which spans four to five orders of magni-
tude in prokaryotes,—six to seven orders of magnitude in eu-
karyotic cells/tissues and 12 orders of magnitude in body flu-
ids [14–16]. Moreover, proteins are subject to more than 200
types of PTMs, which further magnify the number of distinct
protein entities in a sample and sample handling chemistries
[17,18]. Figure 2 illustrates these challenges. In all, from a sin-
gle protein coding genomic loci a myriad of protoforms can
arise, especially in higher eukaryotes, which can be identified
and quantified using high mass accuracy MS.
Protein networks pose a number of data analysis chal-
lenges that are rooted in the fact that proteins cannot be
represented as simple molecular entities. Rather, they op-
erate in a large number of biological contexts, spatial, and
temporal scales and functional states exemplified by protein-
specific properties such as reaction mechanisms, substrate/
motif binding and complex formation. In addition, properties
of protein networks such as information processing, noise,
adaptability, robustness, and even seemingly paradoxical
C© 2015 The Authors. PROTEOMICS published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com66
Proteomics 2015, 15, 3193–3208 3195
Figure 2. Proteins vary greatly within the cell. There are numerous protoforms to consider which arise from alternative splicing of pre-
mRNA and post-tranlational modifications (i). The absolute abundance range of proteins is different in tissue than plasma (ii). Within each
cell type, different proteomes are expressed (iii). The spatial localization of proteins also effects the proteins activity (iv). As a function
of time and/or stimulus, protein levels and/or spacial distribution might differ (v). The activity of proteins is effected by protein-protein
interactions and rewiring of protein networks (vi). All points raised above effect methods to extract the proteome, or parts thereof.
arrangement of components and functions, such as enzyme
promiscuity [19–26]. Moreover, a protein can exist with dif-
ferent variant sequences due to splicing or mutations, and
be subject to different PTMs at different sites, resulting in
a vast number of theoretical combination of PTMs, known
as “mod-forms”, see for example the histone-code [18]. Even
for a protein as well studied as Akt, a recent study found
PTMs affecting a new layer of activation mechanism in cell
cycle progression [27]. Therefore, while there are compelling
reasons to study protein networks of the cell, their analysis
challenges current algorithmic and technical capabilities.
1.3 Protein identification and quantification
There are twomainways to detect and quantify proteins: affin-
ity reagent based methods, exemplified by ELISA, Western
blotting or immuno histochemistry staining, and MS based
peptide identification and quantification, which is mainly
used for research and discovery proteomics. However, the
dynamic range and number of proteins quantifiable using
affinity-reagent based assays is limited [28]. Quantitatively
describing protein networks not only over a large dynamic
range but also multiple samples in a reproducible manner
will lead to a better understanding of the biological protein
network and be a better clinical predictor than single pro-
tein measurements alone. Targeted proteomics is best suited
to meet these needs. Multiple studies clearly demonstrated
the reproducibility of SRM-MS across laboratories [29, 30].
SRM-MS has been applied to quantify protein levels of liver
tissue across 40 strains of BDX mouse [31] and quantitative
trait analysis (QTL) of 78 Saccharomyces cerevisiae strains [32].
Also, SRM assays are relatively easy to establish based either
on prior knowledge (SRM assay repositories) or rapidly de-
veloped using whole protein digest [33]. This is in contrast to
establishing a new (batch of) affinity reagent.
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Figure 3. Typical targeted proteomics workflow. A. Discovery results from LC-MS/MS experiments, protein networkmodeling and literature
search typically form the basis to generate the final candidate list to be quantified by SRM. B. SRM assays for peptides are generated from
extensive LC-MS/MS experiments under consideration of proteotypic peptides generated and best performing transitions per peptide. C.
Data anlysis starts with the primary LC-MS/MS performance examination. If spiked in, stable isotope labeled peptides serve as reference
for consistent quantification. Statistical analysis of peptides quantified serve to identify peptides, and therefore proteins, changing in
abundance. Further analysis include the clustering of data corresponding to proteins quantified and condition. If multiple kinase substrates
were quantified, a consensus motif analysis could identify novel substrate motifs of a kinase. In case the conditions are time course data,
the abundance of proteins can be plotted as a function of time. Using SRM-MS, protein stoichiometry of purified protein complexes can be
determined (to be precise, this method requires newly synthesized externally calibrated reference peptides). The quantification of proteins
and together with sample knowledge integration might lead to signatures which protein signature results in resistant or sensitive samples.
The ultimate analysis is the protein network analysis leading to the prediction of novel perturbations.
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2 Targeted MS considerations
2.1 Overview: targeted MS workflow
A targeted MS-based proteomics experiment consists of mul-
tiple steps and is schematically illustrated in Fig. 3. Specif-
ically, the steps are (1) generation of a hypothesis, a target
list of proteins to test the hypothesis and a fit-for-purpose
quantitation strategy; (2) study design and experimental plan-
ning; (3) sample preparation; (4) method refinement; (5) data
acquisition; (6) analysis and modeling [34–36]. Bioinformat-
ics and computational proteomics are part of each step of
theworkflow. Considerations regarding specificity, precision,
and quantitative accuracy effect all steps of the targeted work-
flow and are discussed in more detail below.
2.2 Step 1: hypothesis development: selection of
targets and quantitation strategy
The target list can be composed of several hundred peptides
to be measured in a multiplexed fashion, allowing for a wide
and versatile set of hypotheses to be tested. Typically the target
list will be chosen from biomarker candidates found in a dis-
covery profiling experiment, previous interest in a pathway,
or from computational analysis identifying pathways and net-
works [8]. The total number of analytes quantified per sample
injection is typically 50–100 peptides.
In general, to test a hypothesis in a basic science model
system, a larger set of proteins is typically measured, while
quantifying biomarkers in a clinical setting for making treat-
ment decisions usually involves a smaller set of proteins.
The selection of a peptide quantification strategy should fol-
low a fit-for-purpose approach to achieve the right level of
specificity, precision, and quantitative accuracy as described
recently in a three-tiered system in Carr and colleagues [37].
This system provides clear guidance with respect to the extent
of analytical validation required for each major application
type, termed Tier 1 to 3 in the publication [37]. In this system,
a “labeled internal standard” refers to the use of a consistent
spike-in for relative quantitation and most commonly con-
sists of heavy-labeled peptides, while a “reference standard”
is as close as possible to the native protein in the sample and
subject to all the same sample preparation steps, its abso-
lute abundance is known, and calibration curves of dilutions
can be established. The most demanding category are assays
for clinical analysis (Tier 1) and require both labeled internal
standards and reference standards, and may need to com-
ply with additional regulatory requirements in each country.
Common Tier 2 designs include measuring relative changes
in protein expression levels and modifications after drug per-
turbation or disease for non-clinical purposes. Exploratory
studies (Tier 3) require some analytical validation, but do not
require labeled internal standards or reference standards, and
consequently have the lowest assay time development costs.
Tier 3 type applications can proceed label-free, at the cost
of somewhat reduced quantitative accuracy. Analytical vali-
dation or reference standards are typically either chemically
synthesized peptides or complex peptidemixtures containing
stable isotopes [38].
All other steps of the SRM-MS method development have
been described in detail elsewhere [36, 39]. Figure 3 depicts
several of these steps and typical downstream analyses. It
should be mentioned, that targeted proteomics described
here is based on protease digest of whole proteins. The re-
sulting peptides may be proteotypic and uniquely identify a
single protein or protein isoformwhereas other peptidesmay
be derived from different proteins. In practice, some proteins
may only be detected with a single peptide that is shared be-
tween closely related proteins, e.g. peptide LVVVGAGGVGK
is shared between RASK, RASN, and RASH_HUMAN – ren-
dering the quantification of a specific protein unreliable. A
special case of proteotypic peptides are quantotypic peptides
which are stoichiometric with total protein abundance and
are not influenced by PTMs under the conditions tested [40].
The choice of the quantified peptides and their suitability to
serve as surrogates for protein identification and quantifica-
tion is therefore an important aspect of targeting proteomics
measurements.
3 Biology applications
3.1 Protein abundance studies
One of the earliest studies using targeted proteomics abso-
lutely quantified G-coupled receptor rhodopsin using chem-
ically synthesized peptides as calibration standard to quan-
tify endogenous levels of membrane bound rhodopsin [41].
One of the earliest perturbed protein network study was car-
ried out by Picotti and colleagues quantifying proteins of
the Krebs Cycle under diauxic shift in Saccharomyces cere-
visiae [16]. The methodology quickly spread to medium sized
target lists and has been used in a variety of basic biology
applications, including pharmacology and developmental bi-
ology. Zhang and coworkers examined the abundance of two
glutathione S-transferase isoforms in human liver cytosol
during detoxification [42]. Heikkinen et al. quantified lev-
els of P450, a drug modifying enzyme, in the drug model
organism Beagle dog [43]. In developmental biology, Betke
et al. examined the differential localization and abundance
of G-beta and G-gamma isoforms of G proteins in pre- and
post-synaptic fractions isolated from the cortex, cerebellum,
hippocampus, and striatum of adult C57Bl6/J mice which
showed significant differences in subcellular localization of
different isoforms and provided an advance in understand-
ing the roles of various subunits in different brain tissues
[44]. Pharmacological and toxicological examinations of 27
cytochrome P450 proteins in Balb/c mouse liver microsomes
and tissue lysates from kidney, lung, intestine, heart, and
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brain across different developmental stages, including preg-
nancy were performed by Hersmann and colleagues [45].
Following the successful quantification of single proteins
or small protein lists, assays for targeted proteomics were
established for entire model organisms [16, 46, 47]. Applica-
tions using medium to large-sized target lists as is the case
for the study of biological networks have pushed technology
development. Chen and coworkers continued the exploratory
studies of human liver by targeting 185 proteins previously
detected in the Chinese Human Liver Proteome Project and
confirmed the presence of 57 targets, 7 of which contained
no information in PeptideAtlas, demonstrating the power of
community efforts contributing to the completion of the Hu-
man Proteome Project [48]. Worboys and coworkers recently
developed assays targeting the human kinome, determining
both proteotypic and quantotypic peptides for 21%of proteins
in the human kinome [40]. Targeted MS has also contributed
to an understanding of development in zebrafish. Groh and
coworkers used a combined global proteomics and compu-
tational approach to generate a candidate list of sex-related
development proteins and established roles for ILF2, ILF3,
ZGC:195027 and other proteins [49].
Systems investigations of the response to perturbations
by targeted proteomics are providing numerous insights in
many higher eukaryotes. Zulak and coworkers investigated
the effects of methyl jasmonate on terpene synthase enzyme
induction and activity in protein extracts of Norway spruce,
demonstrating a coordinated network of chemical defense
response and a prime example of the robustness of biological
systems [50]. Choi and coworkers quantified eight adipokine
proteins in response to hydrogen peroxide-induced oxidative
stress in adipocytes [51]. Bisson and coworkers used affinity
purification and affinity purification MS (AP-MS) to quantify
signaling dynamics of 90 proteins in the GRB2 interactome
in HEK293T cells after growth-factor stimulation [52]. Xiang
and coworkers used cell line models of multiple myeloma
to investigate drug resistance of melphalan by comparing
signaling, apoptosis-regulating, and DNA repair component
proteins, finding a nuclear factor-kappaB signature [53].
Targeted proteomics is increasingly being used to quantify
large numbers of proteins and addressing fundamental ques-
tions in biological networks. Sabido and coworkersmeasured
144 proteins inC57BL/6J and 129Svmice subjected to various
periods of high fat diet, revealing activation of either the per-
oxisomal beta-oxidation pathway or the lipogenesis pathway
in each strain, respectively [54]. Kiel and coworkers quantified
and localized 75% of an Erbb network of 198 signaling pro-
teins acrossHEK293,MCF-7, and keratinocytes, determining
key quantitative parameters for cell-type-specific computa-
tional modeling in this fundamentally important network in
cancer biology [8]. The resulting protein signaling network
is a complex, yet typical, network of signal transduction gov-
erned by protein abundance and protein-protein interactions
to convey phosphorylation signaling as seen in Fig. 1.
Targeted MS is increasingly being used to determine
the stoichiometries of protein complexes a topic that is of
similar importance to the understanding of biological sys-
tems through quantitative modeling. For example, moni-
toring the functional assembly of the human spliceosomal
hPrp19/CDC5L complex under various conditions [55], the
F1F0-ATP synthase super-assembly in H9c2 cardiomyoblasts
undergoing cardiac-like differentiation [56] or the determina-
tion of context-dependent stoichiometry of the nuclear pore
complex in various human cell lines, which showed unantic-
ipated variability [57, 58].
Absolute quantification of proteins using targeted pro-
teomics has considerably matured from single membrane
protein quantification to functional stoichiometry determi-
nations of protein complexes and quantification of protein
networks. A pioneering approach was recently presented by
Soste and coworkers: through literature search and compu-
tational prediction methods sentinel proteins were identified
which report on the state of signaling pathways in a single
SRM-MS analysis. For Saccharomyces cerevisiae 157 proteins
and 152 phosphorylated peptides were identified to reflect
the status of the cellular signaling activity in a single analysis
step, thus providing a broad overview of the state of numerous
functional networks of the cell [59].
3.2 Post-translational modification studies
Targeted MS has proven invaluable for the study of PTMs.
Glinksi and coworkers examined multisite phosphorylation
of trehalose-6-phosphate synthase isozymes in vitro in Ara-
bidopsis [60]. The importance of multisite protein phospho-
rylation and the value of quantifying it by targeted MS were
recently shown for the connexin family of proteins and are
described in a review by Chen and coworkers [61]. Danielson
and coworkers used antibodies specific for 3-nitrotyrosine to
quantify the levels of this modification in alpha-synuclein
residues [62]. Held and coworkers developed a new method
for studying oxidation in response to reactive oxygen species,
termed oxMRM [63]. In a tour-de-force application of their
method, they examined site-specific cysteine oxidation status
of endogenous p53, finding that residue C182 at the dimer-
ization interface of the DNA-binding domain is susceptible to
diamide oxidation. Huang and coworkers studied the effects
of K63 polyubiquitination of EGFR on its endocytosis and
post-endocytotic sorting as mediated by ubiquitin adaptors
[64]. Darwanto and coworkers quantified H2B ubiquitina-
tion and H3 K79 methylation in the U937 human leukemia
cell line and proposed a crosstalk regulatory mechanism be-
tween these two modifications [65]. Wolf-Yadlin and cowork-
ers examined an EFGR network of 222 tyrosine phosphopep-
tides across seven time points following EGF stimulation of
184A1 HMEC cells, demonstrating excellent sensitivity, ro-
bust quantitation, and throughput [66]. A useful case study
and tutorial for targeted proteomics with enrichment is pre-
sented inRardin and coworkers, inwhich they detail amethod
for measuring lysine acetylated peptides from mitochondria
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inmouse liver and targeted quantitation of a lysine acetylation
site in succinate dehydrogenase A [67].
4 Clinical applications
4.1 Introduction to clinical applications
Clinical applications aim to translate new discoveries and
technologies into improving patient outcomes [68] or to in-
crease the understanding of biochemical processes underly-
ing disease etiology. For several decades MS has played a key
role in clinical chemistry, particularly for quantifyingmetabo-
lites and hormones [69, 70]. More recently, much work has
gone into the development of targeted proteomics methods
supporting clinical studies. Specific issues addressed include
handling complexities of tissues and bodily fluids; agreement
of community standards; formation of multi-disciplinary
research teams, and consortia, such as the Clinical Pro-
teomics Tumor Analysis Consortium (CPTAC); demonstra-
tion of inter- and intra-laboratory reproducibility; and proof-
of-concept studies in a variety of clinical applications showing
the feasibility of generating new clinical tests from biomarker
discovery.
4.2 Biomarker development pipeline
The full pipeline of translating biomarker discovery stud-
ies into clinical tests with demonstrated health benefits is
a multi-year process that is costly, uncertain, and arduous
and, because researchers and projects can easily get stuck
in the middle of biomarker development projects, has been
likened to a tar pit [71,72]. Moreover, there are a limited num-
ber of successful biomarkers approved across all technology
platforms, and considerable controversy even surrounds the
success stories, such as PSA testing [73]. Although not the
focus of this review, it is crucial to note that applied statis-
tical testing methodology for biomarker development has it-
self advanced alongside clinical chemistry [73]. A conceptual
guide to overcoming biomarker challenges is presented by
Rifai and coworkers in detail. They define: (i) candidate dis-
covery; (ii) qualification; (iii) verification; (iv) research assay
optimization; (v) biomarker validation; (vi) commercializa-
tion [72]. As mentioned above, peptide quantification strat-
egy should follow a fit-for-purpose approach to achieve the
right level of specificity, precision, and quantitative accuracy
as described in a three-tiered system in Carr and colleagues
[37]. Further, findings of promising biomarkers or signatures
frompreclinical studies should be followed by clinical testing.
The bulk of recent work has focused on candidate discovery
and overcoming the associated challenges related to tissues
and bodily fluids. Targeted proteomics can be used to vali-
date biomarkers found in a project’s discovery phase across
many patient samples with high accuracy and reproducibility
[29, 74]. Cima and coworkers successfully applied this strat-
egy by initially using shotgun data to establish a protein list
of 44 candidates. Consistent quantification of these 44 pro-
teins across a large patient cohort allowed the establishment
of four N-glycosylated protein makers which differentiate pa-
tients with a Gleasson score above or below 7 from blood
serum [75].
4.3 Community efforts and the clinical proteomics
technology assessment for cancer
The complexity in tissues and body fluids presents an enor-
mous signal-to-noise ratio problem [34]. The Human Plasma
ProteomePeptideAtlaswas launched to provide a knowledge-
base for targeted assays [15, 76]. Inspiration for the use of
these assays in the clinical setting comes from the small
molecule clinical chemistry community where targetedMS is
the gold standard for clinical assays quantifying inborn errors
of metabolism, drugs and their metabolites, and steroids and
biogenic amines [69]. In 2006 the National Cancer Institute
(USA) started the Clinical Proteomic Technology Assessment
for Cancer (CPTAC) with the aims of evaluating targeted and
discovery technologies for quantitative analysis in tissues and
biofluids. This program was renewed in 2011 as the CPTAC,
which began focusing on applications [77]. CPTAC mem-
ber laboratories applied standardized methods of multiple
reaction monitoring (MRM) and demonstrated reproducibil-
ity, precision, sensitive quantitation in tissues and biofluids
[78]. Cox and coworkers performed a similar interlaboratory
precision study of IGF-1 in plasma across 130 healthy hu-
man samples and 22 samples from patients with acromegaly,
finding excellent reproducibility [79]. In summary, targeted
proteomics has already established its cross-laboratory repro-
ducibility and robustness and will play a major role in vali-
dating protein biomarker across large patient cohorts.
4.4 Technology development and enrichment
strategies
Over the last decade advances in targeted proteomics have
lead to assay sensitivity for plasma proteins in the low ng/ml
range. In 2004, Kuhn and coworkers used a depletion of
abundant proteins strategy and size exclusion fractionation to
quantitateC-reactive protein, a diagnosticmarker for rheuma-
toid arthritis [80]. Anderson and Hunter targeted 53 medium
and high abundant proteins in plasma, leading to assays for
47 of the proteins covering 4.5 orders of magnitude withmin-
imal sample preparation [81]. Keshishian and coworkers de-
veloped multiplexed assays for six plasma proteins present
in 1–10 ng/ml using strong cation exchange chromatog-
raphy and major abundant protein depletion, but without
immunoaffininty enrichment, demonstrating that the abun-
dance range of typical candidate biomarkers (ng/ml) is achiev-
able with targeted proteomics [82]. Fortin and coworkers also
achieved ng/ml sensitivity without immunoaffinity enrich-
ment by quantitating prostate-specific antigen (PSA) in sera
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from patients with prostate cancer or benign hyperplasia;
moreover, their MS results agreed with established ELISA
tests for PSA [83]. Shi and coworkers used an antibody-free
approach termedPRISM (high-pressure, high-resolution sep-
arations coupled with intelligent selection and multiplexing)
in order to quantitate PSA levels in the range of 50–100 pg/ml,
also with excellent correlation to clinical immunoassays [84].
Shi and coworkers applied the PRISM targeted proteomics
to quantitate AGR2 in human urine at serum at concen-
trations of approximately 130 pg/ml and 10 pg per 100 ug
of total protein mass in urine, respectively, and found in a
proof-of-concept study of 37 urine samples that AGR2/PSA
concentration ratios can distinguish noncancer and cancer
[85]. Fallon and coworkers developed assays for 14 UGT1As
and UGT2Bs across 60 human liver microsomes and match-
ing S9 samples to evaluate metabolism in drug development
[86].
Technology development has also advanced in labeling in-
corporation technology and throughput. Zhao and cowork-
ers developed a synthetic peptide strategy using 18O labeling
strategy for SID-MRM-MS with the ability to produce syn-
thetic peptides for use as internal quantitation standards in
only 1 h with excellent stability [87]. They then utilized these
labeled peptides for absolute quantitation of candidate hepa-
tocellular carcinoma biomarkers vitronectin and clusterin in
undepleted serum samples. Martinez-Morillo and coworkers
developed assays for absolute quantification of apolipoprotein
E isoforms in cerebrospinal fluid and plasma, which are im-
portant in lipidmetabolism in the central nervous system and
are associated with coronary atherosclerosis and Alzheimer’s
disease, and also assessed the effects of chemical modifica-
tions on selected target peptides’ quantitation [88]. Tang and
coworkers used major protein depletion and 1D gel separa-
tion, starting with less than 100 l of serum, obtaining re-
producible quantitation without internal standards down to
200 pg/ml in assays for PRDX6, ADAM12, PAEP, CGB, and
CTSD, which demonstrates that their GeLC-MRM workflow
has sufficient throughput, sensitivity, and costs for an initial
screening of large numbers of candidate biomarkers [89].
Technology development has gone into using PTMs as
handle to enrich for partially low abundant proteins. One
such enrichment strategy is the enrichment of N-glycosylated
peptides and the subsequent PNGase F-catalyzed conversion
of Asn to Asp using solid state extraction method [90, 91]
a method which was successfully applied to serum samples
[75,92]. Upon purification, only themodified peptide is quan-
tified. Stahl-Zeng and coworkers applied minimal fractiona-
tion of isolated N-glycosites to quantitate plasma proteins
over five orders of magnitude, reaching sub-ng/ml range
[93]. Zawadzka and coworkers used both targeted and dis-
covery proteomics to quantify a set of approximately 60 phos-
phopeptides from healthy human plasma following offline
chromatography and immobilized metal ion affinity chro-
matography for phosphopeptide enrichment [94]. Further ad-
vances in targeted proteomics of N-glycosites will undoubt-
edly bring the N-glyco Atlas providing SRM assays for 5568
N-to-D-modified peptide sequences [95]. These SRM-assays
were applied to prostate cancer tissue samples to determine
aggressiveness of tumors using targeted extraction of peptide
sequences from SWATH-MS maps [96].
Another strategy is the enrichment microparticles [97, 98]
or exosomes (or extracellular vesicles) articles from bodily
fluids, e.g. human urin or serum, followed by protein isola-
tion and quantification of peptides using SRM. The exosome
enrichment strategy was applied to various diseases rang-
ing from bladder cancer [99] over diabetic nephropathy [100]
to detecting Mycobacterium tuberculosis peptides in serum of
patients with active or latent M. tuberculosis infection [101].
4.5 Immuno-affinity SRM
While immuno-reagents are commonly used to deplete the
most abundant proteins in plasma they can also be used
for enrichment of low abundant proteins. A commonly used
technique is known as stable isotope standards and cap-
ture by anti-peptide antibodies (SISCAPA) [102]. Dupuis and
coworkers quantified staphylococcal enterotoxins in foods by
applying a combination immunocapture and protein stan-
dard absolute quantification (PSAQ) method, which uses
isotope-labeled enterotoxins as internal standards [103]. Oe
and coworkers used immune capture of amyloid betas in
cerebral spinal fluid as potential biomarkers of Alzheimer’s
disease achieving limits of quantitation down to 200 pg/ml
[104]. Berna and coworkers used immune capture to develop
assays to quantify myosin light chain 1 in rat serum as a
biomarker of cardiac necrosis to predict drug-induced car-
diotoxicity over a range of 0.13 – 6.62 nM [105]. Nicol and
coworkers used an immunoaffinity approach to quantify car-
incoembryonic antigen (CEA), secretory leukocyte peptidase
inhibitor, tissue factor pathway inhibitor 1,2 (TFPI/TFPI2),
and metalloproteinase inhibitor 1 (TIMP1) in sera samples
from lung cancer patients down to low ng/ml levels [106].
Hoofnagle and coworkers quantified the cancer marker thy-
roglobulin in serumusing an immunoaffinity approach down
to a limit of detection of 2.6 ng/ml [107].
Immunoaffinity targeted proteomics can also be used in
combination with additional enrichment techniques to reach
low limits of quantitation.Ahn and coworkers used a variation
of SISCAPA with a combination of phytohemagglutinin-L4
(L-PHA) for N-linked glycan capture and a monoclonal anti-
peptide TIMP1 antibody conjugated to magnetic beads to
quantitate the cancer candidate biomarker TIMP1, which is
present at approximately 0.8 ng/ml in serumusing only 1.7l
of serum from a patient with colorectal cancer [108]. Using
online chromatography for affinity capture instead of offline
magnetic beads, Neubert and coworkers quantified a marker
for gastroesophageal reflux disease, pepsin/pepsinogen, in
the saliva of healthy volunteers down to a range of 0.17 to
0.67 ng/ml, providing the most sensitive and specific test to
date [109]. A few years later, Neubert and coworkersmade use
of robotic sample preparation and sequential immunoaffinity
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capture of the protein NGF using magnetic beads followed
by online affinity capture of a signature NGF peptide, which
is the first report of this combination technique, and allowed
for quantitation of NGF to 7.03 to 450 pg/ml in a clinical trial
for chronic pain [110].
Immunoaffinity techniques can also be useful for quanti-
tating proteins in the presence of autoantibodies. Thyroglob-
ulin (Tg) is used tomonitor patients after treatment for differ-
entiated thyroid carcinoma and is often accompanied by the
presence of auto-antibodies that interfere with immunoas-
says. Kushnir and coworkers overcame these challenges by
enriching serum samples with a rabbit polyclonal antibody
for Tg and immunoaffinity purification of a signature Tg pep-
tide, with a lower limit of quantitation of 0.5 ng/ml [111].
Immunoaffinity techniques are also amenable to multi-
plexing. Using an approach known as mass spectrometric
immunoassay (MSIA), Krastins and coworkers rapidly devel-
oped assays for 16 different target proteins and their isoforms
across seven different clinically important areas and ranging
in concentration from pg/ml to ng/ml in bona fide clinical
samples [112]. Recently, Peterman and coworkers applied the
MSIA approach to detect insulin and its analogues using a
pan-insulin antibody over a range from 1.5 to 960 pM [113].
Other immune-MRM efforts are conducted by the Paulovich
laboratory to overcome limit of detection issues in complex
samples and eliminate the current bottleneck of translating
biomarkers found in basic science studies to clinical practice
[114]. Further advances in the field concern the generation of
immuno-MRMmonoclonal antibodies suitable for SRM and
conventional antibody applications [115].
4.6 Cardiovascular disease applications
Perhaps themain advantage of targetedMS-based proteomics
over ELISA assays is their multiplexing capability, which is of
key importance for biomarker development in disease appli-
cationswithmany putative biomarkers such as cardiovascular
disease and cancer. Kuzyk and coworkers developed a mix-
ture of 45 peptide standards in EDTA-plasma without affinity
depletion or enrichment and found that 31 of the 45 are
putative markers of cardiovascular disease [116]. Keshishian
and coworkers developed quantitative assays without im-
munoaffinity enrichment for six proteins of clinical relevance
to cardiac injury ranging from 2 to 15 ng/ml and measured
these proteins across three time points in six patients un-
dergoing alcohol septal ablation for hypertrophic obstructive
cardiomyopathy [117]. Addona and coworkers used a combi-
nation of discovery and targeted proteomics in the context
of planned myocardial infarction (PMI) for treatment of hy-
pertrophic cardiomyopathy and myocardial infarction (MI)
[118]. Samples of blood directly from patient hearts before,
during, and after PMI allowed identification of 121 candidate
biomarker proteins, over 100 of which were novel. Targeted
proteomics was then applied to peripheral plasma from con-
trols and patients with PMI or MI, suggesting verification
of candidate biomarkers [118]. Huillet and coworkers used
the PSAQ-SRM approach to quantitate cardiovascular dis-
ease biomarkers LDH-B, CKMB, myoglobin, and troponin
I, in serum samples from myocardial infarction patients
[119]. Domanski and coworkers developed assays with 135
stable-isotope labeled peptides for quantitation of 67 candi-
date biomarkers of cardiovascular disease spanning the top
seven most abundant orders of magnitude of concentration
in whole plasma with a 30 min assay time, performing 85
technical replicates, which showed excellent sensitivity and
retention time accuracy [120]. Further, solid state N-glyco en-
richment strategies can be used to enrich to monitor cardiac
resynchronization therapy in serum from a canine model
[121].
4.7 Cancer applications
The heterogeneity and complexity present in the numerous
types of cancer presents an enormous opportunity but sig-
nificant challenges for targeted proteomics to make trans-
formative contributions. Much technology development has
gone into tissue preparation and quantitation of candidate
biomarkers addressing the dual challenges of using a lim-
ited amount of material in which the candidate biomarker
may also be low abundant. DeSouza and coworkers quanti-
fied amarker of endometrial cancer, pyruvate kinaseM1/M2,
in biopsied tissue at 85 nmol/g compared to 21–26 nmol/g
in nonmalignant tissue using the mTRAQ labeling method,
compared to only a 2x elevation initially determined by dis-
covery iTRAQproteomics, suggesting that the dynamic range
for quantitation may be compressed in discovery scans [122].
Chen and coworkers developed quantitative assays for 22 pro-
teins in theWnt/beta-catenin signaling pathway in colon can-
cer cell lines and applied them to frozen colon tissue sections
and laser capture microdissected tumor cells [123]. Elschen-
broich and coworkers combined discovery and targeted pro-
teomics to develop assays for serous-type epithelial ovarian
cancer discovering a panel of 51 candidate proteins and then
using synthetic peptides (13 proteins) and stable isotope la-
bel standards (four proteins) for targeted quantification in as-
cites in serum, providing proof-of-concept validation for this
strategy [124]. Remily-Wood and coworkers used pathway
analysis to develop 95 quantitative assays including synthetic
peptide standards for proteins of interest in colon, lung,
melanoma, leukemias, and myelomas, which are published
online in a Quantitative Assay Database [125]. Selevsek and
coworkers developed multiplexed assays with stable isotope
dilution standards to analyze 16 proteins associatedwith blad-
der cancer in urine with excellent analytical performance and
limits of quantitation limits in the low ng/ml range [126].
Clinical proteomics in cancer has also addressed chal-
lenges of integrating genomic data such as mutations. Wang
and coworkers demonstrated that altered protein products
resulting from somatic mutations can be quantified by tar-
geted proteomics by developing assays for Ras proteins and
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applying them in colorectal and pancreatic tumor tissue and
premalignant pancreatic cyst fluids [127]. He and cowork-
ers recently developed assays to quantitate ERG isoforms in
TMPRSS2-ERG positive VCaP cell line and two prostate can-
cer tissue samples [128].
In 2011 a complete verification pipeline of biomarker can-
didates in plasma was presented in a tour-de-force study by
Whiteaker and coworkers [129]. They integrated 13 datasets
from discovery proteomics and genomics to arrive at >1000
candidate proteins in a mouse model of breast cancer and
used data-dependent prioritization to triage candidates, de-
veloping assays for 88 proteins evaluated across 80 plasma
samples, finding 36 over-expressed proteins with excellent
analytical performance. Their data-dependent triage of can-
didates used a MS approach termed accurate inclusion mass
screening (AIMS), which is essentially an efficient bridge
from discovery to targeted proteomics that uses inclusion-list
dependent acquisition on an orbitrap mass spectrometer to
verify the presence of a candidate (Jaffe et al., 2008).
Hu¨ttenhain and coworkers also completed a tour-de-force
complete verification pipeline of biomarker candidates by
generating assays for 1000 cancer-related proteins and used
a data-dependent triage strategy by first examining candi-
date proteins’ detectability in plasma and urine samples [130].
They subsequently detected 182 proteins in depleted plasma,
spanning five orders ofmagnitude in abundance and 408 pro-
teins in urine. They then profiled 83 patient plasma samples
for 34 of the candidate biomarkers using heavy-labeled syn-
thetic peptides, finding that their targeted proteomics assays
allowed for reproducible quantitation.
Biomarker discovery and verification has also been pur-
sued for post-translationally modified proteins. Cima and
coworkers followed a two-stage strategy for biomarker discov-
ery, starting with a discovery scan comparing the serum N-
linked glycoproteome of PTEN conditional knockout model
of prostate cancer to wild-type and then developed targeted
assays for 39 human orthologs, which were then quanti-
fied in the sera of 143 prostate cancer patients and controls
over an abundance range of six orders of magnitude [75].
Computational analysis derived a signature for diagnosis and
prognosis of prostate cancer. In a followup study, Kalin and
coworkers used the N-linked glycoprotein capture and assays
to quantitate candidate biomarkers in sera of 57 patients with
metastatic prostate cancer [131]. Computational analysis in-
tegrated known prognostic factors with candidate N-linked
glycoproteins derived new nomograms with potentially im-
proved accuracy. Cerciello and coworkers used a three stage
approach for identification of biomarker candidates in the
serum of malignant pleural mesothelioma [132]. First they
screened a collection of relevant cell lines and discovered 125
candidate cell surface N-linked glycoprotein peptides. They
then developed assays for 51 candidates and screened sera
from five patients. In the third stage, the diagnostic potential
of 51 candidate peptides was assessed through targeted pro-
teomics of 75 patient sera samples, with a balanced design
of 25 malignant pleural mesothelioma, 25 healthy donors,
and 25 non-small cell lung cancer patients. Computational
analysis found a seven glycopeptide signature for malignant
pleural mesothelioma with better discrimination than the
FDA approved ELISA assay for mesothelin (Mesomark R©).
Targeted proteomics has been applied successfully to
formalin-fixed, paraffin-embedded (SFPE) tissue. Sprung and
coworkers quantified 114 peptides in FFPE clear cell renal
cell carcinomas andHer2 overexpression in FFPE breast can-
cer samples and determined by comparison with cell lines
that lysine-containing peptides can be used for quantitation
and the feasibility of performing targeted proteomics studies
on FFPE tissues [133]. Takadate and coworkers performed a
discovery scan on eight FFPE resectable, node-positive pan-
creatic ductal adenocarcinoma, and five FFPE noncancerous
pancreatic ducts and selected 170 of 1229 candidate proteins
for targeted assay development, which they applied to a co-
hort of 87 cases, finding 14 overexpressed proteins in the
poor vs. better outcome groups, ultimately nominating four
proteins as prognostic markers: ECH1, OLFM4, STML2, and
GTR1 [134]. Pan and coworkers developed assays for five can-
didate biomarkers of pancreatic cancer and quantified them
in plasma obtained from 20 healthy patients, 20 patients with
chronic pancreatitis, 20 with early stage pancreatic ductal ade-
nocarcinoma, finding that three of the markers gelsolin, lu-
mican, and tissue inhibitor of metalloproteinase 1 can distin-
guish pancreatic cancer from controls [135].
5 Conclusion
Targeted proteomics is now a well-established tool for quan-
titative proteomics and is most useful when researchers
can identify a medium-to-large target list (for examples, see
Table 1). Through selection of sentinel proteins, the activa-
tion state of a given cellular process can be monitored [59],
thus extending the coverage of SRM. To date, the technol-
ogy has been mainly applied to clinical proteomics and less
often to basic biological network questions. In the future, tar-
geted proteomics might play a more vital role in characteriz-
ing critical post-translationally modified amino acid residues
and larger biological networks in a large diversity of devel-
opmental stages, disease, contexts, and perturbations. Tar-
geted proteomics should continue to advance in the clinical
setting. Targeted proteomics can contribute to anunderstand-
ing of networks’ responses to treatment, such as examination
of phosphoprotein response in tumor biopsies before and
after treatment. With respect to biomarkers, large collabo-
rative projects such as The Cancer Genome Atlas (TCGA)
and CPTAC are finding numerous biomarker candidates,
which should be pursued through a sustained commitment
to completing the entire biomarker pipeline, which should ei-
ther eliminate candidates or result in validated and valuable
biomarkers translated to clinical practice.
Advances in MS instrumentation will undoubtedly im-
pact the field towards consistently quantifying more proteins
per sample. Similar to SRM-MS, PRM-MS (parallel reaction
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Table 1. Key studies in targeted MSSome key studies chosen from the reference list covering a wide range of applications of SRM-MS
Study Description Assays successfully developed
Biological applications
Hersmann 2014 Quantitation of cytochrome P450’s across
developmental stages and tissues
27 cytochrome P450 proteins
Chen 2014 Human liver proteome 57 out of 185 human liver proteins
Worboys 2014 Human kinome 790 proteotypic peptides targeting 196 human
kinases – 80% with good quantotypic
properties
Wolf-Yadlin 2007 EFGR network across seven time points
following EGF stimulation of 184A1 HMEC
cells
222 tyrosine phosphopeptides in EGFR network
Sabido 2013 Networks activated by a high fat different
across mice strains
144 metabolism related proteins
Bisetto 2013 F1F0-ATP synthase super-assembly in H9c2
cardiomyoblasts undergoing differentiation
Complex stoichiometry determined
Kiel 2014 Erbb network in human cancer cell lines 75% of 198 proteins in the network
Clinical applications
Huttenhain 2013 Glycosites 5568 N-glycosites
Krastins 2013 Samples from seven different clinical areas 16 target proteins spanning pg/ml to ng/ml
Addona 2011 Planned myocardial infarction 121 biomarker candidates
Domanski 2012 Cardiovascular disease 67 candidate biomarkers
He 2014 ERG isoforms in prostate tissue Multiple ERG isoforms
Whiteaker 2011 Biomarker discovery using a mouse model of
breast cancer
88 proteins in 80 plasma samples; 57-plex SRM
and 31-plex immuno-SRM
Huttenhain 2012 Cancer-related proteins in plasma and urine 182 proteins in depleted plasma; 408 in urine
monitoring mass spectrometry) takes advantage of a mass
spectrometer which first selects precursors using a triple
quadrupole and subsequently fragment ions are mass ana-
lyzed in an orbitrap [136]. Using the same instrumentation as
PRM-MS, the instrument method can be adapted to allow for
data independent acquisition [137, 138]. Instead of coupling
a quadrupole with an orbitrap mass analyzer, SWATH-MS
(sequential window acquisition of all theoretical masses) was
implemented on a mass spectrometer which selects the pre-
cursors with a quadrupole and all fragment ions are analyzed
by TOF [139]. First clinical studies using SWATH-MSdemon-
strated the usefulness of the method: Liu and colleagues con-
cluded from the analysis of serum proteins of a longitudinal
twin study that clinical serum biomarkers should be cali-
brated against genetic background and age adjusted [140].
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APPENDIX B
APPENDIX - NOTE ON COLLABORATIONS AND AUTHORSHIP
This thesis research was performed in close collaboration with H. Alexander
Ebhardt. At the beginning of my thesis research he was a postdoctoral fellow
in Ruedi Aebersold’s laboratory at the ETH in Zurich. Towards the end of my
dissertation research he began his own group at University College Dublin. We
held conference calls on a weekly basis and discussed all aspects of my dis-
sertation research. Generally speaking, I performed data analyses and he per-
formed mass spectrometry. We collaborated closely on experimental design and
the interpretation of results. Figures 2.1, 2.2, 3.1, and 5.5 were prepared by H.
Alexander Ebhardt. MTS assays in figure 5.5A were performed by H. Alexander
Ebhardt in his laboratory at University College, Dublin. All other phenotypic
assays were performed by me and figures created by me.
Chapter 6 of my thesis research involved collaboration among 3 laboratories.
In early 2014 I discussed using AP-MS to identify proteins that interact with an-
drogen receptor with H. Alexander Ebhardt because he had expressed interest
in learning the technique in the Aebersold laboratory where there is substantial
expertise in AP-MS. I subsequently learned that Wassim Abida in the Sawyers’
laboratory was already working on this and we decided to collaborate. The
wetlab experiments that comprise chapter 6 were performed by Wassim Abida
in the Sawyers laboratory and proteomics by H. Alexander Ebhardt in the Ae-
bersold laboratory. I analyzed the data and created the figures collaboratively
with Wassim Abida and H. Alexander Ebhardt. We met and discussed approx-
imately weekly.
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APPENDIX C
APPENDIX - MATHEMATICAL MODELING OF DRUG EFFECTS
Mathematical models may be useful abstractions of biological systems that can
clarify mechanisms and make predictions. Modeling may be useful for devel-
oping drug combinations. By predicting higher order drug combinations from
pairs of perturbations an exponentially large search space can be tested first
in silico before being tested in the laboratory – often erroneously referred to as
”validated.” In silico drug combination screening may be a cost effective way to
develop drug combinations.
Modeling perturbation effects has been a central focus of systems biology re-
search and many types of models have been created. Terfve and Saez-Rodriguez
presented a four-part taxonmy that group models into ”descriptive or predic-
tive”, and ”network or non-network” [Terfve and Saez-Rodriguez, 2012]. The
”descriptive or predictive” dichotomy depends on whether a model is used
to make quantitative predictions about the behavior of a system in response
to novel perturbations and includes models such as regression, differential
equations, and bayesian networks [Terfve and Saez-Rodriguez, 2012]. Hastie
and colleagues add an additional distinction: ”discriminative models” relate
the behavior of some outputs given other inputs, i.e. P(Y |X), or ”generative
models” that predict the joint behavior of inputs and outputs, i.e. P(X,Y)
[Hastie et al., 2009]. Discriminative models have the advantage of being rela-
tively simple. In contrast, generative models have the advantage that they can
be sampled from and therefore generate or simulate data. I pursued strategies
from several taxa of models for both training and research purposes:
1. predictive non-network: partial-least squares regression
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2. descriptive network: partial correlations network
3. predictive network: coupled-system of ordinary differential equations
Each modeling strategy has a set of equations and assumptions; algorithm
& numerical implementation; model assessment; predictions & interpretation
[Hastie et al., 2009]. I focused predominantly on using pre-existing modeling
tools and therefore was concerned with model assessment, predictions and in-
terpretation. Whether a modeling strategy incorporates ”prior knowledge”,
such as pathways in databases is another important consideration that might
be added to the taxa proposed by Terfve and Saez-Rodrigues. I chose not to
incorporate prior knowledge into my modeling, partly for simplicity and partly
to compare the structure of networks learned de novo from data to databases.
C.1 Partial least-squares regression model
C.1.1 Introduction & Methods
In regression models involving drug responses typically the data are modeled as
predicting a phenotype such as cell proliferation or apoptosis y given an input
matrixX of (phospho)-protein values [Lee et al., 2012]. The general multivariate
linear regression model
y = XB +  (C.1)
requires finding the matrix of coefficients B that minimizes the error of an ob-
jective function. When the objective function is minimizing the sum of squared
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error the solution is given by ordinary least-squares
B = (X>X)−1X>y (C.2)
If the number (phospho)-protein variables exceeds the number of perturba-
tion conditions or if multiple (phospho)-proteins are collinear then B cannot
be found by ordinary least-squares because X>X is singular or ill-conditioned,
i.e., not amenable to downstream analyses [Wehrens and Mevik, 2007]. A way
around this issue is to decompose X and y into a smaller number of linear
combinations of the variables such that as much as possible of the covari-
ance between X and y are described by the components of the decomposition
[Wehrens and Mevik, 2007, Hastie et al., 2009].
There are several ways to perform the decomposition and obtain partial-least
squares regression solutions. Wehrens and Mevik describe a relatively simple
iterative method that uses singular-value decomposition (SVD), which is a prac-
tically useful type of matrix factorization [Wehrens and Mevik, 2007]. First, the
SVD of S = X>y is calculated. The first weight vectors consist of the first left and
right singular vectors w and q to obtain scores
t = Xw (C.3)
u = Yq (C.4)
The loadings are then obtained by regressing against the X scores t
p = X>t (C.5)
q = Y>t (C.6)
In the next iteration n+1 outer products tp> and tq> are subtracted from the data
matrices
Xn+1 = Xn − tp> (C.7)
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Yn+1 = Yn − tp> (C.8)
The next component is estimated from the SVD of the updated cross-product
X>n+1Yn+1 and vectors t,w,u,q and p are saved as columns in matrices W, T,
Q, and P [Wehrens and Mevik, 2007]. Typically, a user will choose 10 com-
ponents and use the cross-validation error to choose an optimal number of
components. The R package ’pls’ provides numerical implementations of sev-
eral PLSR algorithms [Wehrens and Mevik, 2007]. Partial least-squares regres-
sion has been successfully applied to understanding relationships between
(phospho)-proteins and drug response [Lee et al., 2012].
C.1.2 Results
The overall quality of the models can be assessed by cross-validation per-
formance on withheld data, e.g., finding the Pearson correlation co-efficient
between data and model. In my drug combination studies I used a leave-
each-drugs-combinations-out cross-validation scheme used by Molinelli and
coworkers [Molinelli et al., 2013]. Because the dataset contains 6 one-drug and
15 two-drug combinations there are 6 pairs of training and test sets used.
If model assessment is satisfactory then feature selection can be performed
whereby the magnitude of coefficient in the regression model is used to rank
order the importance of each (phospho)-protein in predicting drug response
phenotypes [Hastie et al., 2009]. Here model performance was poor with Pear-
son correlation coefficients between data and model averaging 0.22 and the first
two components explaining less than 50% of the variance. The exception is
for combinations involving temsirolimus with a correlation coefficient of 0.84.
Similar results were obtained for integrated dataset with SRM and RPPA mea-
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Figure C.1: PLSR performance on withheld data indicates poor predic-
tive power for most drug combinations except combinations including
temsirolimus.
surements. The models were not deemed to be of sufficient quality to use for
feature selection or prediction. There are many other methods for linear regres-
sion including random forest, elastic net, lasso, ridge, and principal components
regression. I tried a few of them off-the-shelf but did not see a significant in-
crease in performance on withheld data. It is entirely possible that a nonlinear
regression method would have better performance.
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C.2 Undirected network model with partial correlations
Finding important interactions in data can be challenging due to numerous indi-
rect correlations that can swamp the signal [Stein et al., 2015]. Methods that can
clean correlations and identify direct interactions have led to breakthroughs in
diverse scientific problems including protein structure prediction through find-
ing coupled amino-acid residues across multiple sequence alignments that form
3D contacts [Marks et al., 2011]. One method to clean correlations is estimation
of partial correlations. For random variables a, b, and c rescaled to standard
normals the partial correlation between a and b given c is
rab|c =
rab − rbcrac√
1 − r2ac
√
1 − r2bc
(C.9)
where r is the Pearson correlation coefficient [Stein et al., 2015]. For multi-
variate normals the inverse of the empirical covariance matrix gives the ma-
trix of partial correlations. Non-zero partial correlations can be considered
edges in a network model, sometimes called gaussian graphical models, con-
centration graphs, conditional independence graphs, or Markov random fields
[Opgen-Rhein and Strimmer, 2007]. Typically there are more (phospho)-protein
variables p than measurements n so the empirical covariance matrix can-
not be inverted. The GeneNet method uses a sophisticated technique called
”shrinkage” that involves shrinking or setting some partial correlations to zero
[Opgen-Rhein and Strimmer, 2007, Hastie et al., 2009].
The output from the GeneNet algorithm of edges in the partial correlation
network model were filtered for statistical significance with corrected p-values
less than 0.05 and the strongest 50 edges were retained for visual clarity. The
resulting network model is shown in figure C.2. Some edges are expected based
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on prior knowledge. For example, KLK2 and KLK3 are both under androgen
regulation; beta-catenin and e-cadherin are important regulations of cell adhe-
sion and motility; pAKT and pIRS1 are connected by an important feedback
loop.
Connections in the partial correlations network model may indicate cou-
pling of biological processes and pathway crosstalk. For example, edges among
MTOR, cyclinD1 and pPDK1 indicate coordination between growth pathways
and cell cycle. Similarly edges among fatty acid synthesis enzymes ACACA,
FASN, HSP90 and STAT3 suggest that fatty acid synthesis may be coupled to
the stress response and STAT signaling in prostate cancer cells. Co-targeting
these pathways with AR or PI3K/AKT inhibitors may enhance their efficacy.
A partial correlations network model is a relatively simple network analysis
method that is useful for rapid hypothesis generation.
C.3 Coupled-system of nonlinear ordinary differential equa-
tions
Network models of biochemical systems that can be used for knowledge dis-
covery and also to predict effects of perturbations are among the most useful
[Terfve and Saez-Rodriguez, 2012]. The modeler typically needs to make trade-
offs between model complexity and simplicity. One class of complex models are
Michaelis-Menten models. These require detailed knowledge of reactions and
fitting of reaction constants and are therefore impractical for new investigations
of systems with more than about 20 (phospho)-proteins [Nelander et al., 2008].
A simpler class of models are Hopfield-type networks that were originally
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Figure C.2: Network of partial correlations showing top 50 strongest
edges.
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studied in neural networks to represent connectivity, activation, and memory
[Hopfield, 1982]. Despite their relative simplicity these networks are capable
of complex behaviors present in biological systems, such as non-linearity, feed-
back, oscillations, memory, robustness, fine-scale tunability, modularity, stable
points, stable cycles, bifurcations, apparently random fluctuations, and mod-
eling drug synergy [Hopfield, 1982, Nelander et al., 2008, Molinelli et al., 2013,
Miller et al., 2013]. Hopfield-type networks are systems of coupled, non-linear
ordinary differential equations. Even very simple systems of first-order fi-
nite difference equations can exhibit complex dynamical behavior [May, 1976].
There are challenges in both constructing Hopfield-type network models and
analyzing them.
The Hopfield-type network model investigated here was first used in the
Sander group by Nelander and colleagues in 2008 and has the form
dxµ1
dt
= βi arctan
 P∑
j,i
(wi jx
µ
j (t) + u
µ
i )
 − αixµi (t) (C.10)
Where the network structure of p (phospho)-proteins is given by wi j and the
time derivative of each (phospho)-protein xi in perturbation µ is determined by
the sum of three terms: the sum of perturbation effect µ on node xi and its effect
on xi’s neighbors x j, plus a restoring force αxi that represents the tendency of the
system to relax following a perturbation; α and β are constants that modulate
the strength of these terms; arctan is a sigmoidal function that models saturation
effects.
To fit the models from single timepoint measurements 24 hours following
perturbation the system is assumed to be at steady-state. Biologically speak-
ing this may not be correct because several of the drugs are inducing apoptosis.
Molinelli and colleagues were able to derive useful and predictive models in
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melanoma cells under this assumption [Molinelli et al., 2013]. The perturbation
µ can in principal have time dependence but is assumed to be constant here.
This means biologically that the intra-cellular drug concentration is not chang-
ing over the 24 hour period when the (phospho)-protein measurements were
acquired and also not changing over the 72 hour period up to when the models
are simululated.
To construct models, an iterative unconstrained global optimization algo-
rithm is required. Models are optimized by minimizing a cost function
C(W) = β
P∑
i
N∑
µ
(
xµi (tl) − xµ∗i
)2
+ λ
P∑
i
N∑
j,i
δ(wi j) (C.11)
δ(wi j) =

1 if wi j , 0
0 if wi j = 0
(C.12)
where the first term represents the sum-of-squares error between model xµ∗i and
data at perturbation µ summed over all P (phospho)-proteins and N perturba-
tions; the second term represents sparsity and an indicating function assigns
a 1 to any non-zero interaction term wi j; the relative strength of the error cost
is controlled by the constant β and non-sparsity cost by λ, which can be tuned
empirically to minimize cost on training data. Construction of these models is
considered a challenging problem in machine learning called structure learning
[Hastie et al., 2009].
Nelander and colleagues developed their own algorithm COPIA to con-
struct models that uses an iterative combination of Monte-Carlo and gra-
dient calculations called back propagation to minimize the cost function
[Nelander et al., 2008]. Back propagation is one of the earliest methods de-
veloped to construct Hopfield-type networks or neural networks. The COPIA
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method works well in practice but does not run quickly for systems with more
than 50 (phospho)-proteins.
Molinelli and colleagues developed a new iterative method for systems with
> 50 (phospho)-proteins that constructs Hopfield-type models by implementing
a two-part strategy; first, a custom adaptation of the belief propagation algo-
rithm calculates marginal probabilities for each of eleven discrete values for wi j;
second, models are instantiated from these marginal probability distributions
by initial random sampling followed by a belief propagation-guided decimation
algorithm [Molinelli et al., 2013]. The term ’belief propagation’ originated in the
artificial intelligence research community where ’beliefs’ are encoded as prob-
ability statements, often of conditional independence between variables, and
’propagation’ refers to iteratively updating these probability statements among
variables, also termed message passing. Because of the random sampling steps
the BP method is run typically 1,000 times to generate an ensemble of models
for analysis.
Models constructed by BP can be evaluated by assessing performance on
withheld data through a cross-validation scheme. Here I used the same scheme
as for partial least-squares regression, i.e., a leave-each-drugs-combinations-out.
Because the dataset contains 6 one-drug and 15 two-drug combinations there
are 6 pairs of training and test sets used. I used FORTRAN code published by
Molinelli and colleagues and wrote additional code in R for data wrangling,
visualization, numerically integrating ODE systems to steady-state, and assess-
ing model quality by performance on withheld data. Figure C.3 shows the basic
workflow. This workflow was iterated over a grid of sparsity λ and error β val-
ues to find the best performance on withheld data.
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Figure C.3: Workflow for Hopfield network modeling with belief prop-
agation algorithm, FORTRAN code, and R code. The flow starts in the
upper left corner and moves diagonally to lower right.
Figure C.5 shows the performance of the top ten BP-models with lowest
training error on withheld data for the six leave-each-drugs-combos out test
sets. Some models achieve an r2 better than 0.5, however, a minority of models
have terrible performance comparable to random guessing. Interestingly, per-
formance in the temsirolimus drug set (6) has far less variance and exceeds a
mean of 0.5 r2. The worst performance is seen in the Bez235 set (1). The same
pattern was observed with the performance of the partial least-squares regres-
sion models, suggesting that the behavior of some drugs in combination is much
easier to predict than others.
The conclusion of model assessment indicated caution in terms of analyzing
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Figure C.4: Tuning of the sparsity parameter by assessing performance
on withheld data for the top 60 models with lowest training error.
the models and using them to predict novel drug combinations. I ran a num-
ber of simulated in silico drug perturbations where all pairwise combinations
of proteins, targeted by available drugs were explored in terms of their effects
on viability and KLK3 (or PSA). The idea here is that PSA often correlates with
tumor progression and therefore it could be used as an in vitro surrogate of drug
efficacy. KLK3 could also be considered a readout of AR transcriptional activity
because it is a known target gene of AR. Because AR is considered a driver gene
minimizing its activity is also a desirable objective for drug combinations. Fig-
ure C.6 shows that there are two-drug perturbation strategies that the ensemble
of models predicts will affect KLK3, but no strategies affect cellular phenotypes.
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Figure C.5: Performance of top ten BP-models with lowest training error
on withheld data by Pearson correlation data vs model.
A closer look at two-drug perturbations to minimize KLK3 shown in figure C.7
indicates that the best options include direct inhibition of KLK3 as one of the
two drugs in the combination. I evaluated the commercial availability and did
not think any of these combinations warranted testing experimentally.
For future directions, it is worth noting that constructing dynamic mod-
els from single-timepoint measurements can be error prone [Sachs et al., 2013].
There is often an issue with how accurate the assumption of steady-state
behavior is. In addition, Sachs and coworkers showed that if systems
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Figure C.6: In silico perturbation predictions on cellular phenotypes and
KLK3 show no good two-drug combinations to effect cell phenotypes
but possibly strategies to minimize KLK3.
have complicated time-varying behavior then the models that can be learned
from single-timepoints may be highly dependent on the choice of timepoint,
which is naturally unknown to the experimenters during experimental design
[Sachs et al., 2013]. Therefore, there is a necessity in systems biology to develop
the experimental will and sample throughput in proteomics to acquire time-
series measurements. In his thesis Evan Molinelli worked out extensions of
the BP method to construct models based on time-series data [Molinelli, 2013].
This is a promising direction that should be explored further in systems biol-
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Figure C.7: In silico perturbation predictions on KLK3 minimization re-
veals multiple two-drug combination strategies.
ogy. The proteomics technology is in place to quantitate (phospho)-proteins
either by mass spectrometry or RPPA. Development of PRM assays for cancer-
relevant proteins should enable sufficient coverage of important pathways and
throughput for systems biology [Cifani and Kentsis, ].
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